CN1377419A - 调控外源基因转录的方法 - Google Patents
调控外源基因转录的方法 Download PDFInfo
- Publication number
- CN1377419A CN1377419A CN00813868A CN00813868A CN1377419A CN 1377419 A CN1377419 A CN 1377419A CN 00813868 A CN00813868 A CN 00813868A CN 00813868 A CN00813868 A CN 00813868A CN 1377419 A CN1377419 A CN 1377419A
- Authority
- CN
- China
- Prior art keywords
- promotor
- gene
- sequence
- nitrogen
- plant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 96
- 238000000034 method Methods 0.000 title claims abstract description 46
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 30
- 238000013518 transcription Methods 0.000 title claims abstract description 11
- 230000035897 transcription Effects 0.000 title claims abstract description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 95
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 48
- 235000003869 genetically modified organism Nutrition 0.000 claims abstract description 12
- 230000014509 gene expression Effects 0.000 claims description 55
- 241000196324 Embryophyta Species 0.000 claims description 53
- 229910002651 NO3 Inorganic materials 0.000 claims description 33
- NHNBFGGVMKEFGY-UHFFFAOYSA-N nitrate group Chemical group [N+](=O)([O-])[O-] NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 33
- 239000012634 fragment Substances 0.000 claims description 23
- 238000011144 upstream manufacturing Methods 0.000 claims description 18
- 244000061176 Nicotiana tabacum Species 0.000 claims description 16
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 16
- 241000219793 Trifolium Species 0.000 claims description 15
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 15
- 230000009261 transgenic effect Effects 0.000 claims description 13
- 230000033228 biological regulation Effects 0.000 claims description 10
- 230000008929 regeneration Effects 0.000 claims description 9
- 238000011069 regeneration method Methods 0.000 claims description 9
- 241001465754 Metazoa Species 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 8
- 108700026244 Open Reading Frames Proteins 0.000 claims description 7
- 241000589155 Agrobacterium tumefaciens Species 0.000 claims description 6
- 238000013459 approach Methods 0.000 claims description 6
- 230000002068 genetic effect Effects 0.000 claims description 5
- 235000013311 vegetables Nutrition 0.000 claims description 5
- 241000894006 Bacteria Species 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 238000004520 electroporation Methods 0.000 claims description 4
- 210000001161 mammalian embryo Anatomy 0.000 claims description 4
- 230000008488 polyadenylation Effects 0.000 claims description 4
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 3
- 241000233866 Fungi Species 0.000 claims description 3
- 241001233957 eudicotyledons Species 0.000 claims description 3
- 230000035800 maturation Effects 0.000 claims description 3
- 230000002103 transcriptional effect Effects 0.000 claims description 3
- 230000013020 embryo development Effects 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000001890 transfection Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 17
- 108091026890 Coding region Proteins 0.000 abstract description 7
- 239000013604 expression vector Substances 0.000 abstract description 5
- 108700019146 Transgenes Proteins 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 45
- 108010025915 Nitrite Reductases Proteins 0.000 description 40
- 210000004027 cell Anatomy 0.000 description 19
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 12
- 108700008625 Reporter Genes Proteins 0.000 description 11
- 230000001394 metastastic effect Effects 0.000 description 11
- 206010061289 metastatic neoplasm Diseases 0.000 description 11
- 230000012010 growth Effects 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 10
- 102000053187 Glucuronidase Human genes 0.000 description 8
- 108010060309 Glucuronidase Proteins 0.000 description 8
- 241000219823 Medicago Species 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 230000008034 disappearance Effects 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 241000589158 Agrobacterium Species 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 244000207740 Lemna minor Species 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 235000006439 Lemna minor Nutrition 0.000 description 4
- 108090000913 Nitrate Reductases Proteins 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 230000009466 transformation Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 235000001855 Portulaca oleracea Nutrition 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229910052902 vermiculite Inorganic materials 0.000 description 3
- 235000019354 vermiculite Nutrition 0.000 description 3
- 239000010455 vermiculite Substances 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 2
- 241000589180 Rhizobium Species 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 238000013016 damping Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 230000005017 genetic modification Effects 0.000 description 2
- 235000013617 genetically modified food Nutrition 0.000 description 2
- 101150054900 gus gene Proteins 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000003151 transfection method Methods 0.000 description 2
- PAWQVTBBRAZDMG-UHFFFAOYSA-N 2-(3-bromo-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1F PAWQVTBBRAZDMG-UHFFFAOYSA-N 0.000 description 1
- 241000219194 Arabidopsis Species 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 244000300264 Spinacia oleracea Species 0.000 description 1
- 235000009337 Spinacia oleracea Nutrition 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 108010031100 chloroplast transit peptides Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- XUWPJKDMEZSVTP-LTYMHZPRSA-N kalafungina Chemical compound O=C1C2=C(O)C=CC=C2C(=O)C2=C1[C@@H](C)O[C@H]1[C@@H]2OC(=O)C1 XUWPJKDMEZSVTP-LTYMHZPRSA-N 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000006241 metabolic reaction Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002829 nitrogen Chemical class 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 230000008635 plant growth Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8237—Externally regulated expression systems
- C12N15/8238—Externally regulated expression systems chemically inducible, e.g. tetracycline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Abstract
本发明涉及一种在遗传修饰的生物中调节转基因转录的方法。更具体地,本发明涉及带有目的基因编码序列的表达载体的用途,其中所述目的基因在启动序列的转录控制之下,该启动序列的活性由氮的存在来调控。
Description
发明背景
(a)发明领域
本发明涉及在遗传改变的生物中调控转移基因转录的方法。更特异地,本发明涉及含有在启动子序列(其活性受氮存在调控)转录控制下的目的基因编码序列之表达载体的用途。优选地,该构建体用于转基因豆科植物(例如大豆、苜蓿、牛角花三叶草、鸟足三叶草、豆、豌豆、花生),其生长不受无机氮缺乏影响,而且在发育的任何给定时期通过加入合适的氮源都能进行诱导表达。本发明在更广泛的范围内能用于通过加入任何氮源之任何给定转移基因的诱导表达,只要该生物在缺乏该氮诱导物时能够充分生长;例如在植物界,浮萍(Lemnaminor)能在硝酸盐或铵为氮源时适应性生长;因此转基因浮萍能在硝酸盐为唯一氮源时生长,并且通过添加铵来引发转移基因的表达,只要表达盒含有靠加入铵来启动表达的来自天然基因的启动子。因此本发明提供了在任一生物中通过加入多种氮诱导物来调控转移基因特性之表达的方法。
(b)现有技术描述
氮是生命中必需的分子。所有活生物需要氮以合成氨基酸(蛋白质的构建单元)和核苷酸(核酸的构建单元)。硝酸铵是优选的以化肥形式提供给农作物的的无机氮形式。通过大多数草本植物共同的代谢途径的活性,硝态氮先还原为亚硝酸盐再还原为铵。依赖其种属,部分或所有吸收的硝酸盐在其还原为铵以前,通过木质部移到叶细胞。铵、或其它还原形式的氮也通过根系统被吸收(尽管通常效率较低),但是它们的同化作用不需要还原。这些新吸收的铵或含有铵的分子加入细胞中内源性库,其通过氨基酸和其它氮源分子由铵循环形成。某些种属不易代谢硝态氮,因而不能依赖硝酸盐作为唯一氮源;许多针叶属归为后一类。荚果和其它共生植物种属形成植物王国里第三大类氮使用者。它们通过微生物固定气态氮并与之形成代谢联盟。植物有效利用还原氮生长,因此,这些农作物通过得到土壤中的无机氮能够独立发育。
许多微生物和野生植物种属充分适应了氮源的可得性,因而能在缺乏分子形式氮时完成其生命周期,如果在另一生长环境里能得到,它们能够专一并有效地利用氮源。像大多数同化途径一样,氮同化在细胞中受严谨调控。例如,在各种微生物和植物种属中广泛描述了(综述见Miflin和Lea,第5和12册,植物生物化学(The Biochemistry ofPlant)编码硝酸还原酶(NaR)和亚硝酸还原酶(NiR)(负责还原硝酸盐为铵)的基因的表达。尽管硝酸盐不是参与控制NaR和NiR表达的唯一调控分子,它的存在对起始最终导致这些基因持续转录和翻译的转导级联事件很重要。可见,豆科植物当在缺乏无机氮生长时NaR和NiR基因的表达被抑制。
在某些植物种属中鉴定了NiR启动子(Back等,1991,植物分子生物学(Plant Molecular Biology)17:9-18;Sander等,1995,植物分子生物学27:165-177)。在转基因植物中用报告基因表征了这些启动子的可诱导性,表明需要获得硝酸盐以完全活化转录。
还描述了其它氮源的同化途径,并表征了参与某些路径的基因的启动子。
近15年来遗传转化的微生物被用于生产有用的重组分子,目前正应用于制药、化妆品和护肤品工业。在过去10年里随着将这一普通概念应用到复杂真核生物所需技术的发展,该技术已经从微生物扩展到植物和动物。基本上,编码目的蛋白的基因或者编码负责代谢途径改变产生某种目的分子的酶的基因,以适当的方式与顺式和反式作用调控序列相连,并传递给靶细胞,其以瞬时的或稳定的方式整合到分子机器中。转基因细胞或从转基因细胞再生的组织或生物接着进行转移基因的转录和翻译,从而能够积累目的蛋白,或通过目的酶的活性进行新的代谢反应。
正在出现的分子农业工业(在动物或农作物中生产重组分子)是即将到来的下一世纪最有前景的产业之一。其前景是为工业提供安全和再生分子工厂。目前发展的应用有:生产供治疗和诊断用的低成本单克隆抗体;生产用于治疗慢性或致死性疾病的大量的激素、细胞因子和其它生物活性分子;生产多种血液成分的生物安全替代品;生产用于食品和造纸工业的大量加工酶;生产用于废物处理的低成本酶;以及生产用于化妆品工业的安全的生物活性分子。
这项技术应用的局限常常是由于转基因生物不能积累足够量的重组产品,其原因是由于低的转录效率、信使不恰当的剪接、外源mRNA的不稳定、低的翻译效率、重组蛋白对内源性蛋白酶的超敏感性、或者是重组生物对外源蛋白的超敏感性导致不恰当的和有限的生长,或最坏时对宿主生物产生强的有害效应。当边际利润低、或当处理或处置残余物质导致生物安全或环境问题时,生产水平的不足直接影响应用发展。所需重组产品积累水平的提高是保证分子农业许多应用商业化的一个关键因素。
建议使用可诱导性启动子,并且在某些情况下成功地使用,以抵消所有上述因子联合效果。强的可诱导性启动子成功地产生高的暂时转录效率,其导致外源mRNA和翻译产物的高的暂时积累。因此,当表达的可诱导性与足够的同步蛋白质复性步骤相匹配,获得的每单位的产量比使用组成型表达要高。
研发了几个含可诱导性启动子的表达盒用于微生物生产系统,其中一些目前可用于研究目的。一些可诱导性启动子目前正用于植物(创伤诱导性)或动物(对哺乳动物腺细胞(PPL)特异的)系统,尽管没有利用低成本且生物安全的化学诱导物(如硝酸盐)的报告。
提供调控转移基因在遗传改造的生物中转录的方法是非常可取的。
发明概述
本发明的一个目的是提供调控转移基因在遗传改造生物中转录的方法。
本发明的另一个目的是提供含在启动序列(其活性受氮存在调控)转录控制下之目的基因编码序列的表达载体的用途。
本发明涉及氮可诱导性表达盒用于将外源基因在植物中可控制表达的用途。从以下描述可见,可分离该调控序列,使顺式作用序列适当地与目的基因开放阅读框架相连,由此其转录受加入的特异性氮源控制。
本发明的一个方面,靶系统使用豆科植物种类,因此,如果转基因植物在无硝酸盐培养基上生长,含有氮可诱导性启动子的构建体将在生长期持续低水平转录,从而使得植物生物量积累不会受转基因特征的干扰。加入硝酸盐到生长培养基后,随后几天内相对大量的生物量会被诱导转录。优化诱导时间,进行蛋白质积累以最大量得到的所需重组产品。
尽管以下描述阐明:本发明方便地适合对硝酸盐缺乏的转基因豆科植物之硝酸盐诱导,应该记住,该通用概念也能用于研发其它生产系统,从微生物、植物和动物领域里的多种氮同化系统获益。
在本发明的另一方面,在不通过共生联系进行氮固定的、但可利用多种氮资源(还原的或氧化的)生长的,并因此具有当生长环境里缺乏氮源底物使其氮同化途径之一失活也能充分生长的能力之生物中,氮可诱导性也用于蛋白质最大量生产。利用控制该失活途径中任何基因的转录以驱动目的基因在该生物中表达的表达盒,使得一旦加入以前缺乏的氮源性复合物时,转基因性状可诱导性表达。例如,浮萍是能在硝酸盐或铵中生长的植物;本发明能用于开发带有与目的基因适宜连接的铵可诱导性启动子之表达盒,以使硝酸盐中生长型转基因浮萍植物可被诱导。
按照本发明,提供了调控外源基因在转基因生物中转录的方法,包括如下步骤:
a)用表达构建体制备转基因生物,其中所述构建体至少包含氮可诱导性启动子以及基因的开放阅读框架,其中启动子具有选自SEQ IDNOS:1-13的序列和功能性片段及其衍生物,其中所述启动子与所述外源基因可操作地定位以表达所述基因。
按照本发明优选的实施方案,该方法可进一步包括通过加入或去除氮诱导物调控所述基因转录表达的步骤。
按照本发明优选的实施方案,提供了一种调控外源基因在转基因生物中转录的方法,包括:
a)制备表达构建体,其至少包括一个有或无顺式作用序列的氮可诱导性启动子、基因的开放阅读框架以及在所述构建体3’末端的多聚腺苷酸化信号终止位点,其中所述启动子与所述基因可操作地定位以表达所述基因为了所述基因的转录表达,通过加入或去除氮诱导物来调控该启动子;
b)亚克隆步骤a)的构建体到所述生物的合适转染载体;
c)转移所述载体到所述生物或其细胞的DNA中;并且
d)在合适的培养基上选择转基因体。
按照本发明优选的实施方案,该方法进一步包括以下步骤:
e)将载体导入到合适的根癌土壤杆(Agrobacterium tumefaciens)菌株;
f)使用步骤a)的土壤杆菌株转移T-DNA到植物细胞;
g)在合适培养基中选择所述植物细胞的转基因体;
h)从所述转移基因细胞再生胚或小植株;并且
i)从所述再生胚长为成熟植物。
按照本发明优选的实施方案,可从苜蓿中表达的Nir基因5’上游区域分离顺式作用序列。
按照本发明方法优选的实施方案,所述启动子具有SEQ IDNO:1-13所示的序列和功能性片段及其衍生物。
按照本发明优选的实施方案,生物是植物,更优选地双子叶植物。
按照本发明优选的实施方案,生物是苜蓿或烟草。
按照本发明优选的实施方案,氮诱导物是硝酸盐。
按照本发明优选的实施方案,DNA转移方法是任何合适的转移方法,包括DNA轰击、电穿孔、PEG介导的DNA转移和颈须噬菌体,等等。
按照本发明优选的实施方案,表达构建体包含至少一种氮可诱导性启动子和至少一种顺式或反式作用元件。
按照本发明优选的实施方案,生物是植物、真菌、细菌、酵母或动物。
按照本发明优选的实施方案,从任一参与氮同化途径的基因5’上游区域分离启动子或顺式作用序列。
按照本发明优选的实施方案,从任何其转录受给定氮源的获得调控的基因5’上游区域分离启动子或顺式作用序列。
按照本发明优选的实施方案,启动子或顺式作用序列是其转录活性受在任何活生物环境中任何氮源的加入或去除调控的任何序列。
按照本发明优选的实施方案,从其中分离了启动子或顺式作用序列的生物是任何植物、真菌、酵母、细菌或动物。
按照本发明优选的实施方案,提供了用于增强外源基因在转基因生物中转录的启动子,其包含有/无顺式作用序列的氮可诱导性启动子以表达所述基因,并且被改造成通过加入或去除氮诱导物来调控,用于所述基因的转录表达。
优选地,启动子具有选自SEQ ID NOS:1-13所示的序列和功能性片段及其衍生物。
按照本发明优选的实施方案,提供了与启动子联合使用使得外源基因在转基因生物中表达的终止子,其包含为在所述基因3’末端插入的多聚腺苷酸化信号终止位点,其中所述终止子与所述基因和所述启动子可操作地定位,由此允许所述基因表达。
优选地,终止子具有选自SEQ ID NOS:14-16所示的序列和功能性片段及其衍生物。
用于本发明的下列术语定义如下:
“功能性片段或其衍生物”的表述是指序列SEQ.ID.NOS:1-16的任何衍生物或片段,其可使外源基因得到与SEQ.ID.NOS:1-13所示本发明的启动子或SEQ.ID.NOS:14-16所示本发明的终止子相当的表达水平。
附图说明
图1表示,在硝酸盐营养植物之前(空心柱)和之后(实心柱),在转基因烟草植物叶中使用启动子Nir(SEQ ID NOS:2-13)和终止子NOS之GUS表达水平。按照方法部分中的描述,用功能性定位的全长的和缺失的苜蓿NiR启动子和NOS终止子转化烟草植物,来控制GUS报告基因的转录和终止。在硝酸盐诱导前后按照Jefferson等(1987,EMBO J.13:3901-3907)测定GUS活性。
图2表示,在硝酸盐营养植物之前(空心柱)和之后(实心柱),在转基因烟草植物叶中使用启动子Nir(SEQ ID NOS:2,3,5-6)和终止子Nir(SEQ ID NOS:15-16)之GUS表达水平。按照下面的材料与方法中的描述,用功能性定位的全长的和缺失的苜蓿NiR启动子和NOS终止子转化烟草植物,来控制GUS报告基因转录和终止。在硝酸盐诱导前后按照Jefferson(1987,EMBO J.13:3901-3907)测定GUS活性。
图3表示,在硝酸盐营养植物之前(空心柱)和之后(实心柱),在结瘤的转基因苜蓿植物叶中使用启动子NiR和终止子NoS之GUS表达水平如图3所示。按照Khoudi等(1997,Gene197:343-351)描述,用功能性定位的构建体GC2-E,GC2-B,DC1-D和35S转化基因型为11.9的苜蓿以驱动报告基因GUS的表达。再生后,转基因植物转移到无菌的蛭石上,并用根瘤菌属(Rhizobium)株的Balzac(Nitragin)接种。反复加入无硝酸盐的Hoagland’s溶液让植物生长3周;然后按照Jefferson等(1987,EMBO J 13:3901-3907)描述,测定第一片完全扩展叶中GUS的活性。植物再用40mM硝酸盐施肥2天。再次测定第一片完全扩展叶中GUS活性。此处显示数据为硝酸盐诱导前后GUS比活性的比率。
发明详述
以下详细描述了用来产生能够调控其中报告基因表达的转基因烟草和苜蓿系的方法。可对可以分离氮可诱导性启动子的方法;可以将其连接到用于在植物中表达的构建体的开放阅读框架的方法;可以使用并空间排列构建体的不同顺式和反式作用元件的方法;证明并利用氮的可诱导性的方法加以变化,应该记住以上诸多变化均落在本发明范围内。
在该实施方案中,从苜蓿中用RT-PCR方法,用由植物NiR共有序列推断的引物,首次分离了NiR的cDNA链。再用cDNA链去进行上游/下游基因组步移。然后功能性定位NiR启动子区域和缺失、5’UTR和NiR终止子,以控制报告基因GUS的转录和终止。按照Desgagnes等(1995,植物细胞组织器官培养(Plant Cell Tissue OrganCult.)42:129-140)描述,将该构建体插到合适的表达载体,所述载体用于DNA轰击至烟草和苜蓿叶中,以及用于土壤杆菌介导的DNA转移。这两种DNA转移方法用于证明,通过向培养基中加入或去除硝酸盐可以调控报告基因的表达。材料与方法
生物材料
大肠杆菌DH5α用于进行所有克隆步骤,基因型11.9耐寒苜蓿用于所有实验,包括使用根癌土壤杆菌感染稳定转化。(Desgagnes et al.1995,植物细胞组织器官培养42:129-140)
分离总RNA
主要按照de Vries等(1988,B6第1页,Gevin SB Shilperoot RA编,植物分子生物学手册(Plant Molecular Biology Manual),Dordrecht:Kluwer Academic Publisher)描述的热酚法抽提总RNA。
RT-PCR
用RT-PCR生产来自叶细胞总mRNA的对应于一种丰富的NiRmRNA的DNA片段。从五个公共植物NiR开放阅读框架,即Genbank序列#AB006032(Arabidopsis Nir mRNA)、#X66145(烟草部分NiRmRNA)、#U10419(大豆全NiR编码区)、#X07568(菠菜NiRmRNA)、和#U90429(甘氨酸max NiR全编码区),第一次鉴定保守区。从两个保守区,即编码链5’末端的Nir5-5’GATATTGATGTTAGACTCAAGTGGC3’(SEQ ID NO:17),和3’末端的Nir3-5’CACYSATTCCACTTCCTWGGC3’,推导出简并寡核苷酸。首先用200单位M-MLV逆转录酶(RT)、1μg叶细胞总RNA、4mM dNTP(每种各1mM)、5μM随机六聚体引物在1X M-MLV-RT缓冲液(50mM Tris-HCl,pH8.3,75mM KCl,3mM MgCl2)中在37℃条件下反应1小时,进行逆转录反应。PCR反应在Perkin ElmerCetus GenAmp PCR 9600系统(EG&G,Wellesley,MA)中进行,在1X PCR缓冲液(20mM Tris-HCl pH8.4,50mM KCl,2mM MgCl2)中使用2.5单位Taq DNA聚合酶、2μM Nir5引物、2μM Nir3引物、800μM dNTP(每种各200μM)。使用的循环程序是:起始94℃4分钟,然后94℃1分钟,55℃30秒,72℃3分钟做30个循环。该程序还包括72℃延伸7分钟。
DNA测序
DNA测序按照Sanger等(1997,P.N.A.S.USA,74:5643-5647)描述的进行。
基因组步移
用Clontech实验室通用基因组步移试剂盒(Palo Alto.CA)(Cat.#1807-1)进行从RT-PCR反应克隆的苜蓿Nir cDNA片段的上游步移。用于扩增编码序列上游序列的NiR特异性常规引物是:
Nir1106r-5’TTGTCACATCAGCACATCCGTCTTTGC 3’(SEQID NO:19),和
Nir1061r-5’TCGCCAAGTATCTTGTTTGAGCACTTG 3’(SEQID NO:20)。
扩增的3775bp片段亚克隆到pGEM-TEasy载体(Promega,Madison,WI)(Cat.#A1360)中进一步分析。所得质粒命名为pGNir4c。
用下述NiR特异性引物按上游步移进行下游步移:
Nir1c-5’ATGTCTTCCTTCTCAGTACGTTTCCTC 3’(SEQ IDNO:28),和
Nir138c-5’CAAGTTGATGCATCAAGGTGGGAGCCTAGA 3’(SEQ ID NO:29)。
扩增的3508bp片段亚克隆到pGEM-Teasy载体(Promega,Madison,WI)(Cat.#A1360)中进一步分析,所得质粒命名为PGN3’1。
构建表达盒与载体
使用GUS报告基因的表达分析盒构建如下。用HindIII和EcoRI从pBI101消化无启动子的GUS盒,插到pUC19多克隆位点的HindIII与EcoRI位点中。所得质粒命名为pBI201并用于进一步构建。用通用基因组步移试剂盒中AP2引物作为上游定位引物,PCR扩增Nir上游序列,并且任一常规设计下游引物以SmaI限制位点结束。该四种引物分别定位于基因的5’非翻译区(Nir-23r-Sma-5’AGAGCCGGGAGAAGAGAGTGTGTTTG 3’)(SEQ ID NO:21))、转运肽编码序列末端(Nir51r-Sma-5’TTCTCCCGGGGGACGAGAGATGGATGGT3’)(SEQ ID NO:22))、转运肽编码序列后50bp(Nir103r-Sma-5’TTCTCCCGGGGTTGAA-ACAGGTGCAACTGA3’)(SEQ ID NO:23))和转运肽编码序列后100bp(Nir158r-Sma-5’TTCTCCCGGGTAACCATCTTTTTCCTCA 3’)(SEQ ID NO:24))。以pGNir4c质粒为模板按标准条件进行扩增。
用特异性限制酶消化扩增片段以产生Nir启动子的5’端缺失,事先用AP2和Nir-23r-Sma引物扩增的片段经XmaI消化并将所得片段插入事先以XmaI消化的pBI201中,产生pNir3K-23。除了所用的下游引物分别是Nir51r-Sma、Nir103r-Sma和Nir158r-Sma之外,用相似策略产生pNir3K51、pNir3K103和pNir3K158质粒。插入事先以SmaI和BamHI消化过的pBI201中的AP2-Nir-23-Sma扩增片段用Smal-Bbl II消化,产生pNir2.2K-23。除了所用的下游引物分别是Nir51r-Sma、Nir103r-Sma和Nir158r-Sma之外,相同的策略用于产生pNir2.2K51、pNir2.2K 103和pNir2.2K158质粒。用限制性酶消化验证插入片段的忠实性和方向性。该缺失片段连到pBI201中GUS报告基因的5’末端,用于DNA轰击的瞬时表达研究。一旦鉴定足够的缺失片段,将它们亚克隆到二元植物表达载体例如pBI101(Clonetech)中。
为构建除NiR启动子外在GUS基因下游还包含NiR终止子的盒子,使用下述NiR特异性引物:
Nir2514c-Sac-5’AGAAGAGCTCAGTATATAGGTATTTGGTGA3’(SEQ ID NO:30)
Nir2728c-Sac-5’AGAAGAGCTCTTGTACATTTGGATAAGTCA3’(SEQ ID NO:31)
Nir3029r-Eco-5’AGAAGAATTCGTTTTCCCGATACTTCAACT3’(SEQ ID NO:32)
使用Nir2514c-Sac和Nir3029r-Eco引物PCR扩增出617bp的终止子片段。使用Nir2728c-Sac和Nir3029r-Eco引物PCR扩增出503bp的终止子片段。用SacI和EcoRI消化所得片段,并插入到已缺失了SacI与EcoRI位点间的NOS终止子的含有NiR-GUS构建体的质粒中。
按以下描述将该重组质粒用于通过根癌土壤杆菌感染的稳定整合。土壤杆菌介导的DNA转移和转基因苜蓿系的产生
按照Khoudi等(1997,Gene,197:343-351)描述,用电穿孔将重组质粒导入根癌土壤杆菌株LBA4404。选出的土壤杆菌株在无选择压力(卡那霉素)下与基因型为C5-1的叶盘共培养4天。孵育后,清洗和营养叶片,再在B5H培养基上形成愈伤组织。愈伤组织再转移至SH培养基21天用于胚诱导,转移至BOi2Y培养基28天用于胚发育。从BOi2Y上取下鱼雷状的胚胎置于MS培养基以再生。除了共培养及MS上的再生,在所有培养基中都有卡那霉素。Desgages等对该方法有详细描述(1995,植物细胞组织器官培养42:129-140)。生根的小植株在温室中长到成熟。从基因组DNA用PCR扩增NiR-GUS片段以证实转移基因的整合。所用引物是:Nir-102c-5’CACACTTCTTCACTCACCTCTCAA 3’(SEQ ID NO:25)Nir-2016c-5’ATCTAGGAGGGGCAGACATTG 3’(SEQ ID NOS:26)GUS228r-5’TCGGTATAAAGACTTCGCGCTGAT 3’(SEQ IDNOS:27)
土壤杆菌介导的DNA转移及转基因烟草品系的再生
按照Khoudi等(1997,Gene,197:343-351)描述用电穿孔将重组质粒导入根癌土壤杆菌株LBA4404。选择的株与叶盘在无卡那霉素的MS培养基上共培养2天。此后,外植体转移到选择性培养基(有卡那霉素的MS)。外植体放到培养基上3周使之由转染的细胞形成愈伤组织和苗。将卡那霉素抗性苗转移到发根MS培养基。发根的小植株在温室中长至成熟。从基因组DNA用PCR扩增NiR-GUS片段以证实转移基因的整合。所用引物是:Nir-102c-5’CACACTTCTTCACTCACCTCTCAA 3’(SEQ ID NO:25)Nir-2016c-5’ATCTAGGAGGGGCAGACATTG 3’(SEQ ID NOS:26)GUS228r-5’TCGGTATAAAGACTTCGCGCTGAT 3’(SEQ ID NOS:27)硝酸盐诱导
转基因的和未转基因的烟草和苜蓿植物在无硝酸盐的蛭石培养基上生长。通过反复加入无硝酸盐的Hoagland’s的溶液(Hoagland和Varmon,1950,Circular 347,California Agr.Exp.Stat.Berkeley)保持无机盐平衡。用浓度为5gL-1的20-20-20肥料或用补充了40mM硝酸盐的Hoagland’s的溶液浇灌植物进行硝酸盐的诱导。烟草叶中的NiR启动子活性
在转录和翻译融合中GUS报告基因的上游放置NiR来源的启动子。本发明中NiR启动子5’缺失的分析在于:(1)包含编码区起始ATG上游2813bp的推定的全长启动子。(2)启动子的1905bp的版本,和(3)启动子更短的1111bp的版本。启动子的3’末端融合到GUS编码区的5’末端以形成转录和翻译融合体。所分析的翻译融合体允许产生β-葡糖醛酸糖苷酶,其包含(1)NiR叶绿体转运肽,(2)具有NiR的额外17个氨基酸的NiR转运肽,和(3)具有NiR的额外36个氨基酸的NiR转运肽。导入烟草植物中的NiR启动子的5’和3’缺失的12种组合如图1所示。
使用土壤杆菌介导的转染方法(Khoudi等,1997,Gene197:343-351)转移基因构建体到烟草植物。将转基因植物转移到生长室,并分析硝酸盐营养之前和之后其叶中β-葡糖醛酸糖苷酶含量。小植株第一片伸展的叶中测定的β-葡糖醛酸糖苷酶的平均水平如图1所示。
所有NiR来源的启动子显示对硝酸盐诱导的反应性。无论启动子截短与否,通常观察到β-葡糖醛酸糖苷酶的表达增加5-10倍,表明在起始ATG上游的前1.1kb中含有重要的硝酸盐应答元件。NiR启动子的5’和3’缺失都导致β-葡糖醛酸糖苷酶活性的重要改变。使用2.8kb启动子得到最高水平的GUS表达,表明远上游区域对叶中NiR的表达水平有调控作用。
启动子与GUS编码区的翻译性融合根据启动子5’末端的延伸之不同产生多种表达水平。然而,所有3种5’末端截短的最短的融合体(含有融合到β-葡糖醛酸糖苷酶氨基末端的17个氨基酸的NiR转运肽)都恒定地产生最高水平的活性。这种短的翻译融合,与上游启动子区域的最长延伸一起,导致最强的启动子(3kb+50)。当被诱导时,该特异性构建体产生的GUS表达水平比用35S-GUS-NOS构建体得到的多13倍。
当考虑启动子最长的5’延伸时,与GUS基因(3kb-5)转录融合的有效性比短的翻译融合(3kb+50)低7倍。然而在其诱导的状态下,在含有3kb-5启动子缺失的植物中,GUS表达水平比在35S-GUS-NOS植物中观察到的高1,8倍多。
总之,此处结果清楚表明了苜蓿NiR基因上游的序列能够驱动外源基因在烟草植物中高的和可诱导性的表达。NiR终止子的有效性
用含有功能性定位的之启动子NiR和缺失(SEQ ID NOS:2,3,5,6)、35S,和3’UTR序列和终止子(SEQ ID NOS:15和16)的构建体转化烟草植物,以驱动报告基因GUS的转录与终止。如图1所示实验进行生长、硝酸盐诱导和GUS活性测定。结果如图2所示,证明Nir的终止子序列使得转录终止为可翻译的信使RNA。苜蓿叶中NiR启动子活性
用Desgagnes等(1995,植物细胞组织器官培养42:129-140)的土壤杆菌介导的转染方法,得到图3所示的含有基因构建体的转基因苜蓿植物。体外将植物转移到生长室使其行正常营养性生长。每个转基因系的切条在蛭石上生长并用无硝酸盐的Hoagland培养基培养。两周后,用Nitragin(Lipha Tech inc.,Milwaukee,WI)接种根。接种两周后,在根上形成根瘤。根瘤植物继续其营养性生长至少另一周,进行β-葡糖醛酸糖苷酶活性(诱导前)的荧光测定。测定后,用含有40mmolKNO3的Hoagland培养基浇灌植物。诱导后两天,测定叶β-葡糖醛酸糖苷酶活性,以评估苜蓿叶中NiR启动子的硝酸盐诱导性。结果如图3所示。结果表明:当加入硝酸盐到根瘤苜蓿植物中时,NiR启动子诱导GUS报告基因的表达。总之,后一系列结果都证明了:当硝酸盐同化取代气态氮固定时,能够利用NiR启动子的可诱导性正调控苜蓿植物中外源基因的表达。
尽管本发明与其特定的实施方案一起被描述,应该理解,其能作进一步修改。本申请意在包括一般地参考本发明原则的任何改变、运用或调整,还包括在本发明所属领域内已知的或惯例的实践中对本发明的偏离,只要其中涉及了本发明以及应用了以上阐明的重要特性,和如下所附权利要求的范围。
序列表
D'AOUST,Marc-André
MEDICAGO INC.
<120> 调控外源基因转录的方法
<130> 14149-3"PCT"
<150> US 60/157,133
<151> 1999-10-04
<160> 32
<170> FastSEQ for Windows Version 3.0
<210> 1
<211> 3714
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 1ctgtacattc atcttgccgc ctttgcattc acttggccac aaagagtaga gagaaggaag 60agaagagccc agacttcaag aagcgacctt gcaagtgcac tcgagggtca gaaactgtat 120atcatatcta tgtgagagaa aggggaacat ttgagatgga gtccatttac ttgaggtata 180cttattattt tgatcaataa atttgtatac ttcttattta gatcaataaa tttgtcatta 240agctataatc caaaataaat tacgatcaaa tatgcaaatg ttagccagta cttgtgttaa 300acttgatggc atctcttggt ttctttggca atcacatgcc taagaaataa atagtatcat 360atgattgtgt ttggtcagac ttcagagtca gatgactctg tttggataaa cagcttaatt 420aagcgcttat agaatatcat atgattgtgt ttggtcagac ttcagagcat ctcttggttt 480ctctggcaat catatgccta agaaataaat agtatcatat gattgtgttt ggtcagactt 540cagagtcaga tgaccctgtt tgggtaaaca gcttaattaa gtgcttatag aataagcgct 600tatcatataa gtgcttttgt acagttattt ctatgaaagt agaagaaata gtcatattgt 660tttaatataa gctatcctgg agagcttgtg gaaataacca gaaaagaact tatggacacg 720tcatgagctg tttacataag atctccctaa cagtctcaaa agtgtttatg ccagtagata 780aattcaaata agtcaatcta aacagaccct aaatccatta tggtacctat cattttagct 840tattccatct ttattaagaa tgtcatgaga taacataatg ataacacatt attttgacac 900aaatgggcag atctagcaat ttaactctgg agtccttcaa gactgctgtt cttacgaagt 960tcacgtccct gaatcatgtt cctgtatgga agcctgaaag acctcaaatt ctaaaaggtg 1020gcgataaatt gaaggtttac aaaatatacc ctgcgggctt gacacagagg caagctcttt 1080ataccttcca gttcaacggg gatgttgatt tcagaagtca cttggagagc aatccttgtg 1140ccaagtttga agtaattttt gtgtagcata tgttgagcta cctacaattt acatgatcac 1200ctagcattag ctctttcact taactgagag aatgaagttt taggaatgag tatgaccatg 1260gagtcggcat ggctttgtaa tgcctaccct actttggcca actcatcggg gatttacatt 1320cagaaaatat acatgacttc aaccatactt aaaccccttt ttgtaagata actgaatgtt 1380catatttaat gttgggttgt agtgttttta cttgattata tccagacagt tacaagttgg 1440acaacaagat tgtgggtctg tactgttatt tatttatttt ttttttagca gaaacacctt 1500atcttttgtt tcgtttgaat gtagaatgaa aataaaagaa agaaaatata acatcatcgg 1560ccgcgcttgt ctaatttcgg gcagttagga tcctctccgg tcaccggaaa gtttcagtag 1620aagaaacaaa acaccgtgac taaaatgata ctattatttt atttattgtg tttttctttt 1680ttctaccgga actttttaga acggatccca actcgttccg gggccgctac aactgaaaca 1740aaagaagata ttttctctct cttcagaaat gtaagttttc ctttacagat acccattcac 1800catttgattc agatgtggtg actagagata aagcatacta atttgactct tggaaaccca 1860taaagtttat gttatccgtg ttctggacca atccacttgg gggcataacc tgtgtctatg 1920tgtggtttgg tttccattct gatttatgcg gcgacttgta atttaaaatc taggaggggc 1980agacattgaa caatcccaat attttaataa cttatgcaag atttttttta ttaatgagat 2040gatgtgtttg tgactgagat tgagtcatac atttcactaa gaaatggttc caagtaccaa 2100actatcatga cccagttgca aacatgacgt tcgggagtgg tcactttgat agttcaattt 2160catcttggct tcttattcct tttataattc taattcttct tgtgtaaact atttcatgta 2220ttatttttct ttaaaattta catgtcattt attttgcctc actaactcaa ttttgcatat 2280aacaatgata agtgatattt tgactcacaa aatttacatc aaatttcgac atcgtttatt 2340atgttcattg gatgattaac aaatataaca aactttgcaa ctaattaacc accaactgaa 2400tataattaac tataactgtg aaagtagtta accatatttt ttagatgtat atatcatccg 2460ttgaatgtaa ttattcatat atttgaacta agttacccta caacttaaag aacttaaaga 2520actcggtttg agacctgggg acgaaaatgt aatgagactt taatgttgac tttgacaccg 2580caccacatgt gccttttaca tatagtttat atgacaagta atgacaatcc ttgctctatt 2640ataaggcgac ccttagctcc aaccaaagga cgatggagtt aagaaagaaa ctcttgctta 2700cttgtaaggt ccacacttct tcactcacct ctcaatttca tcctacaaaa atgtccaaac 2760ttctctttct cacaatcaca aactcattcc aaacacactc tcttctccaa aaatgtcttc 2820cttctcagta cgtttcctca ccccaccatc catctctcgt cccaacaaaa catggctact 2880atctgctgca actccatcag ttgcacctgt ttcaacacca caagttgatg catcaaggtt 2940ggagcctaga gttgaggaaa aagatggtta ctgggttttg aaggaagagt atagaggggg 3000tattaatcct caggagaaag ttaagattca gaaagaacct atgaagcttt ttatggaagg 3060tgggattaat gatttggcta atatgtctct tgaagagatt gaaagctcta agcttactaa 3120agatgatatt gatgttagac ttaaatggct tggtcttttt catagaagga aacatcattg 3180taagtttttt taccttcttt ttatacctca aagttctctc atactctgta tttgtttatt 3240agtttttgta gacttaaata ttctctttga tttacatagt gaaactccat ttttgtttcc 3300gaaattgtag tgtgtatagt ctagaaaatt aagaagtaga caaaatgatt tatgagattg 3360taaattgtag gctttttatc aatttattaa ttttagagac caaaatttgc ctatcttatt 3420tggaccaata ttgtatgtca ggatcgacat gagtttagta aaatcatgac ggcaccatga 3480ctgtgttgaa gcttctttgt gtaactttaa ccaaaattat atggcacacc ataattatgc 3540aaactcaccg tcgatccaaa catagaaatt cggtgttaat ctttgtgaga ataaaaagct 3600atgagttatg ttgtactaat ttatttccat tgtgaaaatc agatggtaga tttatgatga 3660gactgaaact tccaaatggg gtaacaacaa gtgctcaaac aagatacttg gcga 3714
<210> 2
<211> 2808
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 2ctgtacattc atcttgccgc ctttgcattc acttggccac aaagagtaga gagaaggaag 60agaagagccc agacttcaag aagcgacctt gcaagtgcac tcgagggtca gaaactgtat 120atcatatcta tgtgagagaa aggggaacat ttgagatgga gtccatttac ttgaggtata 180cttattattt tgatcaataa atttgtatac ttcttattta gatcaataaa tttgtcatta 240agctataatc caaaataaat tacgatcaaa tatgcaaatg ttagccagta cttgtgttaa 300acttgatggc atctcttggt ttctttggca atcacatgcc taagaaataa atagtatcat 360atgattgtgt ttggtcagac ttcagagtca gatgactctg tttggataaa cagcttaatt 420aagcgcttat agaatatcat atgattgtgt ttggtcagac ttcagagcat ctcttggttt 480ctctggcaat catatgccta agaaataaat agtatcatat gattgtgttt ggtcagactt 540cagagtcaga tgaccctgtt tgggtaaaca gcttaattaa gtgcttatag aataagcgct 600tatcatataa gtgcttttgt acagttattt ctatgaaagt agaagaaata gtcatattgt 660tttaatataa gctatcctgg agagcttgtg gaaataacca gaaaagaact tatggacacg 720tcatgagctg tttacataag atctccctaa cagtctcaaa agtgtttatg ccagtagata 780aattcaaata agtcaatcta aacagaccct aaatccatta tggtacctat cattttagct 840tattccatct ttattaagaa tgtcatgaga taacataatg ataacacatt attttgacac 900aaatgggcag atctagcaat ttaactctgg agtccttcaa gactgctgtt cttacgaagt 960tcacgtccct gaatcatgtt cctgtatgga agcctgaaag acctcaaatt ctaaaaggtg 1020gcgataaatt gaaggtttac aaaatatacc ctgcgggctt gacacagagg caagctcttt 1080ataccttcca gttcaacggg gatgttgatt tcagaagtca cttggagagc aatccttgtg 1140ccaagtttga agtaattttt gtgtagcata tgttgagcta cctacaattt acatgatcac 1200ctagcattag ctctttcact taactgagag aatgaagttt taggaatgag tatgaccatg 1260gagtcggcat ggctttgtaa tgcctaccct actttggcca actcatcggg gatttacatt 1320cagaaaatat acatgacttc aaccatactt aaaccccttt ttgtaagata actgaatgtt 1380catatttaat gttgggttgt agtgttttta cttgattata tccagacagt tacaagttgg 1440acaacaagat tgtgggtctg tactgttatt tatttatttt ttttttagca gaaacacctt 1500atcttttgtt tcgtttgaat gtagaatgaa aataaaagaa agaaaatata acatcatcgg 1560ccgcgcttgt ctaatttcgg gcagttagga tcctctccgg tcaccggaaa gtttcagtag 1620aagaaacaaa acaccgtgac taaaatgata ctattatttt atttattgtg tttttctttt 1680ttctaccgga actttttaga acggatccca actcgttccg gggccgctac aactgaaaca 1740aaagaagata ttttctctct cttcagaaat gtaagttttc ctttacagat acccattcac 1800catttgattc agatgtggtg actagagata aagcatacta atttgactct tggaaaccca 1860taaagtttat gttatccgtg ttctggacca atccacttgg gggcataacc tgtgtctatg 1920tgtggtttgg tttccattct gatttatgcg gcgacttgta atttaaaatc taggaggggc 1980agacattgaa caatcccaat attttaataa cttatgcaag atttttttta ttaatgagat 2040gatgtgtttg tgactgagat tgagtcatac atttcactaa gaaatggttc caagtaccaa 2100actatcatga cccagttgca aacatgacgt tcgggagtgg tcactttgat agttcaattt 2160catcttggct tcttattcct tttataattc taattcttct tgtgtaaact atttcatgta 2220ttatttttct ttaaaattta catgtcattt attttgcctc actaactcaa ttttgcatat 2280aacaatgata agtgatattt tgactcacaa aatttacatc aaatttcgac atcgtttatt 2340atgttcattg gatgattaac aaatataaca aactttgcaa ctaattaacc accaactgaa 2400tataattaac tataactgtg aaagtagtta accatatttt ttagatgtat atatcatccg 2460ttgaatgtaa ttattcatat atttgaacta agttacccta caacttaaag aacttaaaga 2520actcggtttg agacctgggg acgaaaatgt aatgagactt taatgttgac tttgacaccg 2580caccacatgt gccttttaca tatagtttat atgacaagta atgacaatcc ttgctctatt 2640ataaggcgac ccttagctcc aaccaaagga cgatggagtt aagaaagaaa ctcttgctta 2700cttgtaaggt ccacacttct tcactcacct ctcaatttca tcctacaaaa atgtccaaac 2760ttctctttct cacaatcaca aactcattcc aaacacactc tcttctcc 2808
<210> 3
<211> 2069
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 3gatctcccta acagtctcaa aagtgtttat gccagtagat aaattcaaat aagtcaatct 60aaacagaccc taaatccatt atggtaccta tcattttagc ttattccatc tttattaaga 120atgtcatgag ataacataat gataacacat tattttgaca caaatgggca gatctagcaa 180tttaactctg gagtccttca agactgctgt tcttacgaag ttcacgtccc tgaatcatgt 240tcctgtatgg aagcctgaaa gacctcaaat tctaaaaggt ggcgataaat tgaaggttta 300caaaatatac cctgcgggct tgacacagag gcaagctctt tataccttcc agttcaacgg 360ggatgttgat ttcagaagtc acttggagag caatccttgt gccaagtttg aagtaatttt 420tgtgtagcat atgttgagct acctacaatt tacatgatca cctagcatta gctctttcac 480ttaactgaga gaatgaagtt ttaggaatga gtatgaccat ggagtcggca tggctttgta 540atgcctaccc tactttggcc aactcatcgg ggatttacat tcagaaaata tacatgactt 600caaccatact taaacccctt tttgtaagat aactgaatgt tcatatttaa tgttgggttg 660tagtgttttt acttgattat atccagacag ttacaagttg gacaacaaga ttgtgggtct 720gtactgttat ttatttattt tttttttagc agaaacacct tatcttttgt ttcgtttgaa 780tgtagaatga aaataaaaga aagaaaatat aacatcatcg gccgcgcttg tctaatttcg 840ggcagttagg atcctctccg gtcaccggaa agtttcagta gaagaaacaa aacaccgtga 900ctaaaatgat actattattt tatttattgt gtttttcttt tttctaccgg aactttttag 960aacggatccc aactcgttcc ggggccgcta caactgaaac aaaagaagat attttctctc 1020tcttcagaaa tgtaagtttt cctttacaga tacccattca ccatttgatt cagatgtggt 1080gactagagat aaagcatact aatttgactc ttggaaaccc ataaagttta tgttatccgt 1140gttctggacc aatccacttg ggggcataac ctgtgtctat gtgtggtttg gtttccattc 1200tgatttatgc ggcgacttgt aatttaaaat ctaggagggg cagacattga acaatcccaa 1260tattttaata acttatgcaa gatttttttt attaatgaga tgatgtgttt gtgactgaga 1320ttgagtcata catttcacta agaaatggtt ccaagtacca aactatcatg acccagttgc 1380aaacatgacg ttcgggagtg gtcactttga tagttcaatt tcatcttggc ttcttattcc 1440ttttataatt ctaattcttc ttgtgtaaac tatttcatgt attatttttc tttaaaattt 1500acatgtcatt tattttgcct cactaactca attttgcata taacaatgat aagtgatatt 1560ttgactcaca aaatttacat caaatttcga catcgtttat tatgttcatt ggatgattaa 1620caaatataac aaactttgca actaattaac caccaactga atataattaa ctataactgt 1680gaaagtagtt aaccatattt tttagatgta tatatcatcc gttgaatgta attattcata 1740tatttgaact aagttaccct acaacttaaa gaacttaaag aactcggttt gagacctggg 1800gacgaaaatg taatgagact ttaatgttga ctttgacacc gcaccacatg tgccttttac 1860atatagttta tatgacaagt aatgacaatc cttgctctat tataaggcga cccttagctc 1920caaccaaagg acgatggagt taagaaagaa actcttgctt acttgtaagg tccacacttc 1980ttcactcacc tctcaatttc atcctacaaa aatgtccaaa cttctctttc tcacaatcac 2040aaactcattc caaacacact ctcttctcc 2069
<210> 4
<211> 1220
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 4gatcctctcc ggtcaccgga aagtttcagt agaagaaaca aaacaccgtg actaaaatga 60tactattatt ttatttattg tgtttttctt ttttctaccg gaacttttta gaacggatcc 120caactcgttc cggggccgct acaactgaaa caaaagaaga tattttctct ctcttcagaa 180atgtaagttt tcctttacag atacccattc accatttgat tcagatgtgg tgactagaga 240taaagcatac taatttgact cttggaaacc cataaagttt atgttatccg tgttctggac 300caatccactt gggggcataa cctgtgtcta tgtgtggttt ggtttccatt ctgatttatg 360cggcgacttg taatttaaaa tctaggaggg gcagacattg aacaatccca atattttaat 420aacttatgca agattttttt tattaatgag atgatgtgtt tgtgactgag attgagtcat 480acatttcact aagaaatggt tccaagtacc aaactatcat gacccagttg caaacatgac 540gttcgggagt ggtcactttg atagttcaat ttcatcttgg cttcttattc cttttataat 600tctaattctt cttgtgtaaa ctatttcatg tattattttt ctttaaaatt tacatgtcat 660ttattttgcc tcactaactc aattttgcat ataacaatga taagtgatat tttgactcac 720aaaatttaca tcaaatttcg acatcgttta ttatgttcat tggatgatta acaaatataa 780caaactttgc aactaattaa ccaccaactg aatataatta actataactg tgaaagtagt 840taaccatatt ttttagatgt atatatcatc cgttgaatgt aattattcat atatttgaac 900taagttaccc tacaacttaa agaacttaaa gaactcggtt tgagacctgg ggacgaaaat 960gtaatgagac tttaatgttg actttgacac cgcaccacat gtgcctttta catatagttt 1020atatgacaag taatgacaat ccttgctcta ttataaggcg acccttagct ccaaccaaag 1080gacgatggag ttaagaaaga aactcttgct tacttgtaag gtccacactt cttcactcac 1140ctctcaattt catcctacaa aaatgtccaa acttctcttt ctcacaatca caaactcatt 1200ccaaacacac tctcttctcc 1220
<210> 5
<211> 2863
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 5ctgtacattc atcttgccgc ctttgcattc acttggccac aaagagtaga gagaaggaag 60agaagagccc agacttcaag aagcgacctt gcaagtgcac tcgagggtca gaaactgtat 120atcatatcta tgtgagagaa aggggaacat ttgagatgga gtccatttac ttgaggtata 180cttattattt tgatcaataa atttgtatac ttcttattta gatcaataaa tttgtcatta 240agctataatc caaaataaat tacgatcaaa tatgcaaatg ttagccagta cttgtgttaa 300acttgatggc atctcttggt ttctttggca atcacatgcc taagaaataa atagtatcat 360atgattgtgt ttggtcagac ttcagagtca gatgactctg tttggataaa cagcttaatt 420aagcgcttat agaatatcat atgattgtgt ttggtcagac ttcagagcat ctcttggttt 480ctctggcaat catatgccta agaaataaat agtatcatat gattgtgttt ggtcagactt 540cagagtcaga tgaccctgtt tgggtaaaca gcttaattaa gtgcttatag aataagcgct 600tatcatataa gtgcttttgt acagttattt ctatgaaagt agaagaaata gtcatattgt 660tttaatataa gctatcctgg agagcttgtg gaaataacca gaaaagaact tatggacacg 720tcatgagctg tttacataag atctccctaa cagtctcaaa agtgtttatg ccagtagata 780aattcaaata agtcaatcta aacagaccct aaatccatta tggtacctat cattttagct 840tattccatct ttattaagaa tgtcatgaga taacataatg ataacacatt attttgacac 900aaatgggcag atctagcaat ttaactctgg agtccttcaa gactgctgtt cttacgaagt 960tcacgtccct gaatcatgtt cctgtatgga agcctgaaag acctcaaatt ctaaaaggtg 1020gcgataaatt gaaggtttac aaaatatacc ctgcgggctt gacacagagg caagctcttt 1080ataccttcca gttcaacggg gatgttgatt tcagaagtca cttggagagc aatccttgtg 1140ccaagtttga agtaattttt gtgtagcata tgttgagcta cctacaattt acatgatcac 1200ctagcattag ctctttcact taactgagag aatgaagttt taggaatgag tatgaccatg 1260gagtcggcat ggctttgtaa tgcctaccct actttggcca actcatcggg gatttacatt 1320cagaaaatat acatgacttc aaccatactt aaaccccttt ttgtaagata actgaatgtt 1380catatttaat gttgggttgt agtgttttta cttgattata tccagacagt tacaagttgg 1440acaacaagat tgtgggtctg tactgttatt tatttatttt ttttttagca gaaacacctt 1500atcttttgtt tcgtttgaat gtagaatgaa aataaaagaa agaaaatata acatcatcgg 1560ccgcgcttgt ctaatttcgg gcagttagga tcctctccgg tcaccggaaa gtttcagtag 1620aagaaacaaa acaccgtgac taaaatgata ctattatttt atttattgtg tttttctttt 1680ttctaccgga actttttaga acggatccca actcgttccg gggccgctac aactgaaaca 1740aaagaagata ttttctctct cttcagaaat gtaagttttc ctttacagat acccattcac 1800catttgattc agatgtggtg actagagata aagcatacta atttgactct tggaaaccca 1860taaagtttat gttatccgtg ttctggacca atccacttgg gggcataacc tgtgtctatg 1920tgtggtttgg tttccattct gatttatgcg gcgacttgta atttaaaatc taggaggggc 1980agacattgaa caatcccaat attttaataa cttatgcaag atttttttta ttaatgagat 2040gatgtgtttg tgactgagat tgagtcatac atttcactaa gaaatggttc caagtaccaa 2100actatcatga cccagttgca aacatgacgt tcgggagtgg tcactttgat agttcaattt 2160catcttggct tcttattcct tttataattc taattcttct tgtgtaaact atttcatgta 2220ttatttttct ttaaaattta catgtcattt attttgcctc actaactcaa ttttgcatat 2280aacaatgata agtgatattt tgactcacaa aatttacatc aaatttcgac atcgtttatt 2340atgttcattg gatgattaac aaatataaca aactttgcaa ctaattaacc accaactgaa 2400tataattaac tataactgtg aaagtagtta accatatttt ttagatgtat atatcatccg 2460ttgaatgtaa ttattcatat atttgaacta agttacccta caacttaaag aacttaaaga 2520actcggtttg agacctgggg acgaaaatgt aatgagactt taatgttgac tttgacaccg 2580caccacatgt gccttttaca tatagtttat atgacaagta atgacaatcc ttgctctatt 2640ataaggcgac ccttagctcc aaccaaagga cgatggagtt aagaaagaaa ctcttgctta 2700cttgtaaggt ccacacttct tcactcacct ctcaatttca tcctacaaaa atgtccaaac 2760ttctctttct cacaatcaca aactcattcc aaacacactc tcttctccaa aaatgtcttc 2820cttctcagta cgtttcctca ccccaccatc catctctcgt ccc 2863
<210> 6
<211> 2124
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 6gatctcccta acagtctcaa aagtgtttat gccagtagat aaattcaaat aagtcaatct 60aaacagaccc taaatccatt atggtaccta tcattttagc ttattccatc tttattaaga 120atgtcatgag ataacataat gataacacat tattttgaca caaatgggca gatctagcaa 180tttaactctg gagtccttca agactgctgt tcttacgaag ttcacgtccc tgaatcatgt 240tcctgtatgg aagcctgaaa gacctcaaat tctaaaaggt ggcgataaat tgaaggttta 300caaaatatac cctgcgggct tgacacagag gcaagctctt tataccttcc agttcaacgg 360ggatgttgat ttcagaagtc acttggagag caatccttgt gccaagtttg aagtaatttt 420tgtgtagcat atgttgagct acctacaatt tacatgatca cctagcatta gctctttcac 480ttaactgaga gaatgaagtt ttaggaatga gtatgaccat ggagtcggca tggctttgta 540atgcctaccc tactttggcc aactcatcgg ggatttacat tcagaaaata tacatgactt 600caaccatact taaacccctt tttgtaagat aactgaatgt tcatatttaa tgttgggttg 660tagtgttttt acttgattat atccagacag ttacaagttg gacaacaaga ttgtgggtct 720gtactgttat ttatttattt tttttttagc agaaacacct tatcttttgt ttcgtttgaa 780tgtagaatga aaataaaaga aagaaaatat aacatcatcg gccgcgcttg tctaatttcg 840ggcagttagg atcctctccg gtcaccggaa agtttcagta gaagaaacaa aacaccgtga 900ctaaaatgat actattattt tatttattgt gtttttcttt tttctaccgg aactttttag 960aacggatccc aactcgttcc ggggccgcta caactgaaac aaaagaagat attttctctc 1020tcttcagaaa tgtaagtttt cctttacaga tacccattca ccatttgatt cagatgtggt 1080gactagagat aaagcatact aatttgactc ttggaaaccc ataaagttta tgttatccgt 1140gttctggacc aatccacttg ggggcataac ctgtgtctat gtgtggtttg gtttccattc 1200tgatttatgc ggcgacttgt aatttaaaat ctaggagggg cagacattga acaatcccaa 1260tattttaata acttatgcaa gatttttttt attaatgaga tgatgtgttt gtgactgaga 1320ttgagtcata catttcacta agaaatggtt ccaagtacca aactatcatg acccagttgc 1380aaacatgacg ttcgggagtg gtcactttga tagttcaatt tcatcttggc ttcttattcc 1440ttttataatt ctaattcttc ttgtgtaaac tatttcatgt attatttttc tttaaaattt 1500acatgtcatt tattttgcct cactaactca attttgcata taacaatgat aagtgatatt 1560ttgactcaca aaatttacat caaatttcga catcgtttat tatgttcatt ggatgattaa 1620caaatataac aaactttgca actaattaac caccaactga atataattaa ctataactgt 1680gaaagtagtt aaccatattt tttagatgta tatatcatcc gttgaatgta attattcata 1740tatttgaact aagttaccct acaacttaaa gaacttaaag aactcggttt gagacctggg 1800gacgaaaatg taatgagact ttaatgttga ctttgacacc gcaccacatg tgccttttac 1860atatagttta tatgacaagt aatgacaatc cttgctctat tataaggcga cccttagctc 1920caaccaaagg acgatggagt taagaaagaa actcttgctt acttgtaagg tccacacttc 1980ttcactcacc tctcaatttc atcctacaaa aatgtccaaa cttctctttc tcacaatcac 2040aaactcattc caaacacact ctcttctcca aaaatgtctt ccttctcagt acgtttcctc 2100accccaccat ccatctctcg tccc 2124
<210> 7
<211> 1160
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 7gatcccaact cgttccgggg ccgctacaac tgaaacaaaa gaagatattt tctctctctt 60cagaaatgta agttttcctt tacagatacc cattcaccat ttgattcaga tgtggtgact 120agagataaag catactaatt tgactcttgg aaacccataa agtttatgtt atccgtgttc 180tggaccaatc cacttggggg cataacctgt gtctatgtgt ggtttggttt ccattctgat 240ttatgcggcg acttgtaatt taaaatctag gaggggcaga cattgaacaa tcccaatatt 300ttaataactt atgcaagatt ttttttatta atgagatgat gtgtttgtga ctgagattga 360gtcatacatt tcactaagaa atggttccaa gtaccaaact atcatgaccc agttgcaaac 420atgacgttcg ggagtggtca ctttgatagt tcaatttcat cttggcttct tattcctttt 480ataattctaa ttcttcttgt gtaaactatt tcatgtatta tttttcttta aaatttacat 540gtcatttatt ttgcctcact aactcaattt tgcatataac aatgataagt gatattttga 600ctcacaaaat ttacatcaaa tttcgacatc gtttattatg ttcattggat gattaacaaa 660tataacaaac tttgcaacta attaaccacc aactgaatat aattaactat aactgtgaaa 720gtagttaacc atatttttta gatgtatata tcatccgttg aatgtaatta ttcatatatt 780tgaactaagt taccctacaa cttaaagaac ttaaagaact cggtttgaga cctggggacg 840aaaatgtaat gagactttaa tgttgacttt gacaccgcac cacatgtgcc ttttacatat 900agtttatatg acaagtaatg acaatccttg ctctattata aggcgaccct tagctccaac 960caaaggacga tggagttaag aaagaaactc ttgcttactt gtaaggtcca cacttcttca 1020ctcacctctc aatttcatcc tacaaaaatg tccaaacttc tctttctcac aatcacaaac 1080tcattccaaa cacactctct tctccaaaaa tgtcttcctt ctcagtacgt ttcctcaccc 1140caccatccat ctctcgtccc 1160
<210> 8
<211> 2904
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 8ctgtacattc atcttgccgc ctttgcattc acttggccac aaagagtaga gagaaggaag 60agaagagccc agacttcaag aagcgacctt gcaagtgcac tcgagggtca gaaactgtat 120atcatatcta tgtgagagaa aggggaacat ttgagatgga gtccatttac ttgaggtata 180cttattattt tgatcaataa atttgtatac ttcttattta gatcaataaa tttgtcatta 240agctataatc caaaataaat tacgatcaaa tatgcaaatg ttagccagta cttgtgttaa 300acttgatggc atctcttggt ttctttggca atcacatgcc taagaaataa atagtatcat 360atgattgtgt ttggtcagac ttcagagtca gatgactctg tttggataaa cagcttaatt 420aagcgcttat agaatatcat atgattgtgt ttggtcagac ttcagagcat ctcttggttt 480ctctggcaat catatgccta agaaataaat agtatcatat gattgtgttt ggtcagactt 540cagagtcaga tgaccctgtt tgggtaaaca gcttaattaa gtgcttatag aataagcgct 600tatcatataa gtgcttttgt acagttattt ctatgaaagt agaagaaata gtcatattgt 660tttaatataa gctatcctgg agagcttgtg gaaataacca gaaaagaact tatggacacg 720tcatgagctg tttacataag atctccctaa cagtctcaaa agtgtttatg ccagtagata 780aattcaaata agtcaatcta aacagaccct aaatccatta tggtacctat cattttagct 840tattccatct ttattaagaa tgtcatgaga taacataatg ataacacatt attttgacac 900aaatgggcag atctagcaat ttaactctgg agtccttcaa gactgctgtt cttacgaagt 960tcacgtccct gaatcatgtt cctgtatgga agcctgaaag acctcaaatt ctaaaaggtg 1020gcgataaatt gaaggtttac aaaatatacc ctgcgggctt gacacagagg caagctcttt 1080ataccttcca gttcaacggg gatgttgatt tcagaagtca cttggagagc aatccttgtg 1140ccaagtttga agtaattttt gtgtagcata tgttgagcta cctacaattt acatgatcac 1200ctagcattag ctctttcact taactgagag aatgaagttt taggaatgag tatgaccatg 1260gagtcggcat ggctttgtaa tgcctaccct actttggcca actcatcggg gatttacatt 1320cagaaaatat acatgacttc aaccatactt aaaccccttt ttgtaagata actgaatgtt 1380catatttaat gttgggttgt agtgttttta cttgattata tccagacagt tacaagttgg 1440acaacaagat tgtgggtctg tactgttatt tatttatttt ttttttagca gaaacacctt 1500atcttttgtt tcgtttgaat gtagaatgaa aataaaagaa agaaaatata acatcatcgg 1560ccgcgcttgt ctaatttcgg gcagttagga tcctctccgg tcaccggaaa gtttcagtag 1620aagaaacaaa acaccgtgac taaaatgata ctattatttt atttattgtg tttttctttt 1680ttctaccgga actttttaga acggatccca actcgttccg gggccgctac aactgaaaca 1740aaagaagata ttttctctct cttcagaaat gtaagttttc ctttacagat acccattcac 1800catttgattc agatgtggtg actagagata aagcatacta atttgactct tggaaaccca 1860taaagtttat gttatccgtg ttctggacca atccacttgg gggcataacc tgtgtctatg 1920tgtggtttgg tttccattct gatttatgcg gcgacttgta atttaaaatc taggaggggc 1980agacattgaa caatcccaat attttaataa cttatgcaag atttttttta ttaatgagat 2040gatgtgtttg tgactgagat tgagtcatac atttcactaa gaaatggttc caagtaccaa 2100actatcatga cccagttgca aacatgacgt tcgggagtgg tcactttgat agttcaattt 2160catcttggct tcttattcct tttataattc taattcttct tgtgtaaact atttcatgta 2220ttatttttct ttaaaattta catgtcattt attttgcctc actaactcaa ttttgcatat 2280aacaatgata agtgatattt tgactcacaa aatttacatc aaatttcgac atcgtttatt 2340atgttcattg gatgattaac aaatataaca aactttgcaa ctaattaacc accaactgaa 2400tataattaac tataactgtg aaagtagtta accatatttt ttagatgtat atatcatccg 2460ttgaatgtaa ttattcatat atttgaacta agttacccta caacttaaag aacttaaaga 2520actcggtttg agacctgggg acgaaaatgt aatgagactt taatgttgac tttgacaccg 2580caccacatgt gccttttaca tatagtttat atgacaagta atgacaatcc ttgctctatt 2640ataaggcgac ccttagctcc aaccaaagga cgatggagtt aagaaagaaa ctcttgctta 2700cttgtaaggt ccacacttct tcactcacct ctcaatttca tcctacaaaa atgtccaaac 2760ttctctttct cacaatcaca aactcattcc aaacacactc tcttctccaa aaatgtcttc 2820cttctcagta cgtttcctca ccccaccatc catctctcgt cccaacaaaa catggctact 2880atctgctgca actccatcag ttgc 2904
<210> 9
<211> 2165
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 9gatctcccta acagtctcaa aagtgtttat gccagtagat aaattcaaat aagtcaatct 60aaacagaccc taaatccatt atggtaccta tcattttagc ttattccatc tttattaaga 120atgtcatgag ataacataat gataacacat tattttgaca caaatgggca gatctagcaa 180tttaactctg gagtccttca agactgctgt tcttacgaag ttcacgtccc tgaatcatgt 240tcctgtatgg aagcctgaaa gacctcaaat tctaaaaggt ggcgataaat tgaaggttta 300caaaatatac cctgcgggct tgacacagag gcaagctctt tataccttcc agttcaacgg 360ggatgttgat ttcagaagtc acttggagag caatccttgt gccaagtttg aagtaatttt 420tgtgtagcat atgttgagct acctacaatt tacatgatca cctagcatta gctctttcac 480ttaactgaga gaatgaagtt ttaggaatga gtatgaccat ggagtcggca tggctttgta 540atgcctaccc tactttggcc aactcatcgg ggatttacat tcagaaaata tacatgactt 600caaccatact taaacccctt tttgtaagat aactgaatgt tcatatttaa tgttgggttg 660tagtgttttt acttgattat atccagacag ttacaagttg gacaacaaga ttgtgggtct 720gtactgttat ttatttattt tttttttagc agaaacacct tatcttttgt ttcgtttgaa 780tgtagaatga aaataaaaga aagaaaatat aacatcatcg gccgcgcttg tctaatttcg 840ggcagttagg atcctctccg gtcaccggaa agtttcagta gaagaaacaa aacaccgtga 900ctaaaatgat actattattt tatttattgt gtttttcttt tttctaccgg aactttttag 960aacggatccc aactcgttcc ggggccgcta caactgaaac aaaagaagat attttctctc 1020tcttcagaaa tgtaagtttt cctttacaga tacccattca ccatttgatt cagatgtggt 1080gactagagat aaagcatact aatttgactc ttggaaaccc ataaagttta tgttatccgt 1140gttctggacc aatccacttg ggggcataac ctgtgtctat gtgtggtttg gtttccattc 1200tgatttatgc ggcgacttgt aatttaaaat ctaggagggg cagacattga acaatcccaa 1260tattttaata acttatgcaa gatttttttt attaatgaga tgatgtgttt gtgactgaga 1320ttgagtcata catttcacta agaaatggtt ccaagtacca aactatcatg acccagttgc 1380aaacatgacg ttcgggagtg gtcactttga tagttcaatt tcatcttggc ttcttattcc 1440ttttataatt ctaattcttc ttgtgtaaac tatttcatgt attatttttc tttaaaattt 1500acatgtcatt tattttgcct cactaactca attttgcata taacaatgat aagtgatatt 1560ttgactcaca aaatttacat caaatttcga catcgtttat tatgttcatt ggatgattaa 1620caaatataac aaactttgca actaattaac caccaactga atataattaa ctataactgt 1680gaaagtagtt aaccatattt tttagatgta tatatcatcc gttgaatgta attattcata 1740tatttgaact aagttaccct acaacttaaa gaacttaaag aactcggttt gagacctggg 1800gacgaaaatg taatgagact ttaatgttga ctttgacacc gcaccacatg tgccttttac 1860atatagttta tatgacaagt aatgacaatc cttgctctat tataaggcga cccttagctc 1920caaccaaagg acgatggagt taagaaagaa actcttgctt acttgtaagg tccacacttc 1980ttcactcacc tctcaatttc atcctacaaa aatgtccaaa cttctctttc tcacaatcac 2040aaactcattc caaacacact ctcttctcca aaaatgtctt ccttctcagt acgtttcctc 2100accccaccat ccatctctcg tcccaacaaa acatggctac tatctgctgc aactccatca 2160gttgc 2165
<210> 10
<211> 1316
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 10gatcctctcc ggtcaccgga aagtttcagt agaagaaaca aaacaccgtg actaaaatga 60tactattatt ttatttattg tgtttttctt ttttctaccg gaacttttta gaacggatcc 120caactcgttc cggggccgct acaactgaaa caaaagaaga tattttctct ctcttcagaa 180atgtaagttt tcctttacag atacccattc accatttgat tcagatgtgg tgactagaga 240taaagcatac taatttgact cttggaaacc cataaagttt atgttatccg tgttctggac 300caatccactt gggggcataa cctgtgtcta tgtgtggttt ggtttccatt ctgatttatg 360cggcgacttg taatttaaaa tctaggaggg gcagacattg aacaatccca atattttaat 420aacttatgca agattttttt tattaatgag atgatgtgtt tgtgactgag attgagtcat 480acatttcact aagaaatggt tccaagtacc aaactatcat gacccagttg caaacatgac 540gttcgggagt ggtcactttg atagttcaat ttcatcttgg cttcttattc cttttataat 600tctaattctt cttgtgtaaa ctatttcatg tattattttt ctttaaaatt tacatgtcat 660ttattttgcc tcactaactc aattttgcat ataacaatga taagtgatat tttgactcac 720aaaatttaca tcaaatttcg acatcgttta ttatgttcat tggatgatta acaaatataa 780caaactttgc aactaattaa ccaccaactg aatataatta actataactg tgaaagtagt 840taaccatatt ttttagatgt atatatcatc cgttgaatgt aattattcat atatttgaac 900taagttaccc tacaacttaa agaacttaaa gaactcggtt tgagacctgg ggacgaaaat 960gtaatgagac tttaatgttg actttgacac cgcaccacat gtgcctttta catatagttt 1020atatgacaag taatgacaat ccttgctcta ttataaggcg acccttagct ccaaccaaag 1080gacgatggag ttaagaaaga aactcttgct tacttgtaag gtccacactt cttcactcac 1140ctctcaattt catcctacaa aaatgtccaa acttctcttt ctcacaatca caaactcatt 1200ccaaacacac tctcttctcc aaaaatgtct tccttctcag tacgtttcct caccccacca 1260tccatctctc gtcccaacaa aacatggcta ctatctgctg caactccatc agttgc 1316
<210> 11
<211> 2971
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 11ctgtacattc atcttgccgc ctttgcattc acttggccac aaagagtaga gagaaggaag 60agaagagccc agacttcaag aagcgacctt gcaagtgcac tcgagggtca gaaactgtat 120atcatatcta tgtgagagaa aggggaacat ttgagatgga gtccatttac ttgaggtata 180cttattattt tgatcaataa atttgtatac ttcttattta gatcaataaa tttgtcatta 240agctataatc caaaataaat tacgatcaaa tatgcaaatg ttagccagta cttgtgttaa 300acttgatggc atctcttggt ttctttggca atcacatgcc taagaaataa atagtatcat 360atgattgtgt ttggtcagac ttcagagtca gatgactctg tttggataaa cagcttaatt 420aagcgcttat agaatatcat atgattgtgt ttggtcagac ttcagagcat ctcttggttt 480ctctggcaat catatgccta agaaataaat agtatcatat gattgtgttt ggtcagactt 540cagagtcaga tgaccctgtt tgggtaaaca gcttaattaa gtgcttatag aataagcgct 600tatcatataa gtgcttttgt acagttattt ctatgaaagt agaagaaata gtcatattgt 660tttaatataa gctatcctgg agagcttgtg gaaataacca gaaaagaact tatggacacg 720tcatgagctg tttacataag atctccctaa cagtctcaaa agtgtttatg ccagtagata 780aattcaaata agtcaatcta aacagaccct aaatccatta tggtacctat cattttagct 840tattccatct ttattaagaa tgtcatgaga taacataatg ataacacatt attttgacac 900aaatgggcag atctagcaat ttaactctgg agtccttcaa gactgctgtt cttacgaagt 960tcacgtccct gaatcatgtt cctgtatgga agcctgaaag acctcaaatt ctaaaaggtg 1020gcgataaatt gaaggtttac aaaatatacc ctgcgggctt gacacagagg caagctcttt 1080ataccttcca gttcaacggg gatgttgatt tcagaagtca cttggagagc aatccttgtg 1140ccaagtttga agtaattttt gtgtagcata tgttgagcta cctacaattt acatgatcac 1200ctagcattag ctctttcact taactgagag aatgaagttt taggaatgag tatgaccatg 1260gagtcggcat ggctttgtaa tgcctaccct actttggcca actcatcggg gatttacatt 1320cagaaaatat acatgacttc aaccatactt aaaccccttt ttgtaagata actgaatgtt 1380catatttaat gttgggttgt agtgttttta cttgattata tccagacagt tacaagttgg 1440acaacaagat tgtgggtctg tactgttatt tatttatttt ttttttagca gaaacacctt 1500atcttttgtt tcgtttgaat gtagaatgaa aataaaagaa agaaaatata acatcatcgg 1560ccgcgcttgt ctaatttcgg gcagttagga tcctctccgg tcaccggaaa gtttcagtag 1620aagaaacaaa acaccgtgac taaaatgata ctattatttt atttattgtg tttttctttt 1680ttctaccgga actttttaga acggatccca actcgttccg gggccgctac aactgaaaca 1740aaagaagata ttttctctct cttcagaaat gtaagttttc ctttacagat acccattcac 1800catttgattc agatgtggtg actagagata aagcatacta atttgactct tggaaaccca 1860taaagtttat gttatccgtg ttctggacca atccacttgg gggcataacc tgtgtctatg 1920tgtggtttgg tttccattct gatttatgcg gcgacttgta atttaaaatc taggaggggc 1980agacattgaa caatcccaat attttaataa cttatgcaag atttttttta ttaatgagat 2040gatgtgtttg tgactgagat tgagtcatac atttcactaa gaaatggttc caagtaccaa 2100actatcatga cccagttgca aacatgacgt tcgggagtgg tcactttgat agttcaattt 2160catcttggct tcttattcct tttataattc taattcttct tgtgtaaact atttcatgta 2220ttatttttct ttaaaattta catgtcattt attttgcctc actaactcaa ttttgcatat 2280aacaatgata agtgatattt tgactcacaa aatttacatc aaatttcgac atcgtttatt 2340atgttcattg gatgattaac aaatataaca aactttgcaa ctaattaacc accaactgaa 2400tataattaac tataactgtg aaagtagtta accatatttt ttagatgtat atatcatccg 2460ttgaatgtaa ttattcatat atttgaacta agttacccta caacttaaag aacttaaaga 2520actcggtttg agacctgggg acgaaaatgt aatgagactt taatgttgac tttgacaccg 2580caccacatgt gccttttaca tatagtttat atgacaagta atgacaatcc ttgctctatt 2640ataaggcgac ccttagctcc aaccaaagga cgatggagtt aagaaagaaa ctcttgctta 2700cttgtaaggt ccacacttct tcactcacct ctcaatttca tcctacaaaa atgtccaaac 2760ttctctttct cacaatcaca aactcattcc aaacacactc tcttctccaa aaatgtcttc 2820cttctcagta cgtttcctca ccccaccatc catctctcgt cccaacaaaa catggctact 2880atctgctgca actccatcag ttgcacctgt ttcaacacca caagttgatg catcaaggtt 2940ggagcctaga gttgaggaaa aagatggtta c 2971
<210> 12
<211> 2232
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 12gatctcccta acagtctcaa aagtgtttat gccagtagat aaattcaaat aagtcaatct 60aaacagaccc taaatccatt atggtaccta tcattttagc ttattccatc tttattaaga 120atgtcatgag ataacataat gataacacat tattttgaca caaatgggca gatctagcaa 180tttaactctg gagtccttca agactgctgt tcttacgaag ttcacgtccc tgaatcatgt 240tcctgtatgg aagcctgaaa gacctcaaat tctaaaaggt ggcgataaat tgaaggttta 300caaaatatac cctgcgggct tgacacagag gcaagctctt tataccttcc agttcaacgg 360ggatgttgat ttcagaagtc acttggagag caatccttgt gccaagtttg aagtaatttt 420tgtgtagcat atgttgagct acctacaatt tacatgatca cctagcatta gctctttcac 480ttaactgaga gaatgaagtt ttaggaatga gtatgaccat ggagtcggca tggctttgta 540atgcctaccc tactttggcc aactcatcgg ggatttacat tcagaaaata tacatgactt 600caaccatact taaacccctt tttgtaagat aactgaatgt tcatatttaa tgttgggttg 660tagtgttttt acttgattat atccagacag ttacaagttg gacaacaaga ttgtgggtct 720gtactgttat ttatttattt tttttttagc agaaacacct tatcttttgt ttcgtttgaa 780tgtagaatga aaataaaaga aagaaaatat aacatcatcg gccgcgcttg tctaatttcg 840ggcagttagg atcctctccg gtcaccggaa agtttcagta gaagaaacaa aacaccgtga 900ctaaaatgat actattattt tatttattgt gtttttcttt tttctaccgg aactttttag 960aacggatccc aactcgttcc ggggccgcta caactgaaac aaaagaagat attttctctc 1020tcttcagaaa tgtaagtttt cctttacaga tacccattca ccatttgatt cagatgtggt 1080gactagagat aaagcatact aatttgactc ttggaaaccc ataaagttta tgttatccgt 1140gttctggacc aatccacttg ggggcataac ctgtgtctat gtgtggtttg gtttccattc 1200tgatttatgc ggcgacttgt aatttaaaat ctaggagggg cagacattga acaatcccaa 1260tattttaata acttatgcaa gatttttttt attaatgaga tgatgtgttt gtgactgaga 1320ttgagtcata catttcacta agaaatggtt ccaagtacca aactatcatg acccagttgc 1380aaacatgacg ttcgggagtg gtcactttga tagttcaatt tcatcttggc ttcttattcc 1440ttttataatt ctaattcttc ttgtgtaaac tatttcatgt attatttttc tttaaaattt 1500acatgtcatt tattttgcct cactaactca attttgcata taacaatgat aagtgatatt 1560ttgactcaca aaatttacat caaatttcga catcgtttat tatgttcatt ggatgattaa 1620caaatataac aaactttgca actaattaac caccaactga atataattaa ctataactgt 1680gaaagtagtt aaccatattt tttagatgta tatatcatcc gttgaatgta attattcata 1740tatttgaact aagttaccct acaacttaaa gaacttaaag aactcggttt gagacctggg 1800gacgaaaatg taatgagact ttaatgttga ctttgacacc gcaccacatg tgccttttac 1860atatagttta tatgacaagt aatgacaatc cttgctctat tataaggcga cccttagctc 1920caaccaaagg acgatggagt taagaaagaa actcttgctt acttgtaagg tccacacttc 1980ttcactcacc tctcaatttc atcctacaaa aatgtccaaa cttctctttc tcacaatcac 2040aaactcattc caaacacact ctcttctcca aaaatgtctt ccttctcagt acgtttcctc 2100accccaccat ccatctctcg tcccaacaaa acatggctac tatctgctgc aactccatca 2160gttgcacctg tttcaacacc acaagttgat gcatcaaggt tggagcctag agttgaggaa 2220aaagatggtt ac 2232
<210> 13
<211> 1383
<212> DNA
<213> 人工序列
<220>
<223> 待用作启动子用于调控外源基因表达的序列
<400> 13gatcctctcc ggtcaccgga aagtttcagt agaagaaaca aaacaccgtg actaaaatga 60tactattatt ttatttattg tgtttttctt ttttctaccg gaacttttta gaacggatcc 120caactcgttc cggggccgct acaactgaaa caaaagaaga tattttctct ctcttcagaa 180atgtaagttt tcctttacag atacccattc accatttgat tcagatgtgg tgactagaga 240taaagcatac taatttgact cttggaaacc cataaagttt atgttatccg tgttctggac 300caatccactt gggggcataa cctgtgtcta tgtgtggttt ggtttccatt ctgatttatg 360cggcgacttg taatttaaaa tctaggaggg gcagacattg aacaatccca atattttaat 420aacttatgca agattttttt tattaatgag atgatgtgtt tgtgactgag attgagtcat 480acatttcact aagaaatggt tccaagtacc aaactatcat gacccagttg caaacatgac 540gttcgggagt ggtcactttg atagttcaat ttcatcttgg cttcttattc cttttataat 600tctaattctt cttgtgtaaa ctatttcatg tattattttt ctttaaaatt tacatgtcat 660ttattttgcc tcactaactc aattttgcat ataacaatga taagtgatat tttgactcac 720aaaatttaca tcaaatttcg acatcgttta ttatgttcat tggatgatta acaaatataa 780caaactttgc aactaattaa ccaccaactg aatataatta actataactg tgaaagtagt 840taaccatatt ttttagatgt atatatcatc cgttgaatgt aattattcat atatttgaac 900taagttaccc tacaacttaa agaacttaaa gaactcggtt tgagacctgg ggacgaaaat 960gtaatgagac tttaatgttg actttgacac cgcaccacat gtgcctttta catatagttt 1020atatgacaag taatgacaat ccttgctcta ttataaggcg acccttagct ccaaccaaag 1080gacgatggag ttaagaaaga aactcttgct tacttgtaag gtccacactt cttcactcac 1140ctctcaattt catcctacaa aaatgtccaa acttctcttt ctcacaatca caaactcatt 1200ccaaacacac tctcttctcc aaaaatgtct tccttctcag tacgtttcct caccccacca 1260tccatctctc gtcccaacaa aacatggcta ctatctgctg caactccatc agttgcacct 1320gtttcaacac cacaagttga tgcatcaagg ttggagccta gagttgagga aaaagatggt 1380tac 1383
<210> 14
<211> 3472
<212> DNA
<213> 人工序列
<220>
<223> 待用作终止子用于调控外源基因表达的序列
<400> 14caagttgatg catcaaggtt ggagcctaga gttgaggaaa aagatggtta ctgggttttg 60aaggaagagt atagaggagg tattaatcct caggagaaag ttaagattca gaaagaacct 120atgaagcttt ttatggaagg tgggattaat gatttggcta atatgtctct tgaagagatt 180gaaagctcta agcttactaa agatgatatt gatgttagac ttaaatggct tggtcttttt 240catagaagga aacatcattg taagtttttt tactttcttt ttatacttca aagttctctc 300atactctgta tttgtttatt agtttttgta gacttaaata ttctctttga tttacatagt 360gaaactccat tcttgtttcc gaaattgtag tgtgtatagt ctagaaaatt aagaagtaga 420caaaatgatt tatgagattg taaattgtag gctttttatc aatttattaa ttttagagac 480caaaatttgc ctatcttatt tggaccaatt tattgtatgt taggatcgac atgagtttag 540caaaatcatg acggcaccat gactgtgttg aagcttcttt gtgtaacttt aaccaaaatt 600atatggcaca ccatgattat gcaaactcac cgtcaatcca aacatagaaa ttcagtgtta 660atctttgtga caataaaaaa ctatgagtta tgttgtacta atttatttcc attgtgaaac 720tcagatggta gatttatgat gagactaaaa ctcccaaatg gggtaacaac aagtgctcaa 780acaagatact tggcgagtgt gataaaaaaa tatggcaaag acggatgtgc tgatgtgaca 840acgaggcaga attggcaaat tcgaggtgta acgttacctg atgtccctga aattcttaag 900ggccttgcag aggtcggctt gacaagtctg cagagtggaa tggacaatgt tcgaaaccca 960gttggtaacc ctcttgctgg tattgaccct gatgagattg ttgatacaag accttacacc 1020aatttgctgt cccaattcat cactgctaat tcacttggta atccaaccat tacaaacttg 1080taagtctaaa ctatctcatc tttatatttc actcattata tcatattagt agttagttac 1140ttgcattgca agcattacgt gaccgtgtgt agcctctaaa tccttttgat aatatgtgca 1200ggccaaggaa gtggaatgta tgtgtgatag gttcccatga tcttttcgag catccgcata 1260ttaacgatct tgcttatatg cctgctaata aggatggtcg atttggattc aacttattgg 1320tgggtggttt ctttagtccc aagcgatgtg ctgaagcagt tccacttgat gcatgggtct 1380ctgcagatga tgttatccca ctttgtaaag ctgtccttga gacctatagg gacctcggca 1440caagagggaa tagacagaaa accagaatga tgtggttgat cgatgaactt gtaagttacc 1500actttttttc ttcacatatt attaactgaa gtgactttaa cgaccatttt acaattgaaa 1560tttaagtgga ttttagccct atcattacaa gaacaaattt gttaattcac tagcaagagc 1620aattccactt tggcttggac atgacaagtg tttgtgaaat gcaggggata gaagtattca 1680gatcagaggt ggaaaaaaga atgccagaga agaagctaga gagagcatcc aaagaagaac 1740ttgtccaaaa acaatggaaa gaggagacat cttaggtgtt catccacaaa aacaagaagg 1800tttaagctat gttggaattc acattccagt tggtagaatc caagcagatg agatggaaga 1860gctagctcgt atcgccgatg aatacggaac cggagaacta aggctaaccg tggagcaaaa 1920cataataatt ccaaatgtgg aaaactcaaa acttgatgca ttgctaaatg aacctctctt 1980gaaagacaaa ttctcaccag aaccttccat cctaatgaaa acacttgtgg catgcactgg 2040taaccaattt tgtggccaag caataattga aacaaaacaa agagctttaa aagtaactga 2100agaagttgaa agacatgtgg ctgtgagcaa accagtgaga atgcattgga ctggttgtcc 2160taacacttgt ggtcaagttc aggttgctga tattggtttt atgggttgta tggctaggga 2220tgagaatggt aaggctactg aaggtgttga tattttcctt ggtgggagaa ttggaagtga 2280ttctcattta gctgaggtgt ataagaaagg tgtcccttgc aaggacttgg tgcctattgt 2340agctgatatt ttggttaaat attttggagc tgtccaaagg aatagagaag aaggggatga 2400ttaaagtata taggtatttg gtgattttaa ttgcctctac acaaaattat tatgttctgt 2460ccaaaatata aagtcacaag ggataattga gattgagatg cagcacgcca cacatgaact 2520tgtacatttg gataagtcat ttttcattgc tattttataa gttacacttt gaattttata 2580ataaatttta ttttatttca aggaccagat tttataagga aaccgctaat ctaactatct 2640ttactcgtaa tttgtcattt gagagctacg gagatcgttg agtttacgta tgagtgttta 2700gtctcacatt aattatgaat ggtcaaaatg ttaaatttat aagagatgta atctatatac 2760ctaatgcatt aaaaatttgg atggagatgc gacgcccccc ttttttgtgg tcctgaagta 2820tagacttgtt gtcgcttctg gtgcactctc atacttccca acaaggagaa aaaactacca 2880taacaattaa caaactaaca tttgttattt aaaaaaacat acggatactg ttttttcccc 2940atttattagg aagatgatgg cttggatttc aatggctgag tttatttttt ttttggtcgg 3000gagttgaagt atcgggaaaa ctaaatatgc tatgacttta aacattgtgt tgatatatga 3060ttagttttca acttacttaa aaagtggcaa actagtttag tggttctctc ccttccttgt 3120agttcaagga acatgggttt gaactctgtc caaatttttg tactttcaat tatccataca 3180tttaaaagct atataccaca tcattatatt caagtcaatg atcatgcggc ctgccacatt 3240agcatcgatg tacacattaa ttttaagtgg catgaacaca ttaacatttc ataaaagcta 3300tgtgccagat catcattcaa gtctatgcac acatggtcaa cacattagta ccattttttt 3360ttttattgtt gatcagattg gatgtcggta ttgttgtgat gctacaaact caaacaatct 3420ccagctgtta gagaacgtcg aaaatgaatg catcacgggt gcacacttag at 3472
<210> 15
<211> 617
<212> DNA
<213> 人工序列
<220>
<223> 待用作终止子用于调控外源基因表达的序列
<400> 15agtatatagg tatttggtga ttttaattgc ctctacacaa aattattatg ttctgtccaa 60aatataaagt cacaagggat aattgagatt gagatgcagc acgccacaca tgaacttgta 120catttggata agtcattttt cattgctatt ttataagtta cactttgaat tttataataa 180attttatttt atttcaagga ccagatttta taaggaaacc gctaatctaa ctatctttac 240tcgtaatttg tcatttgaga gctacggaga tcgttgagtt tacgtatgag tgtttagtct 300cacattaatt atgaatggtc aaaatgttaa atttataaga gatgtaatct atatacctaa 360tgcattaaaa atttggatgg agatgcgacg cccccctttt ttgtggtcct gaagtataga 420cttgttgtcg cttctggtgc actctcatac ttcccaacaa ggagaaaaaa ctaccataac 480aattaacaaa ctaacatttg ttatttaaaa aaacatacgg atactgtttt ttccccattt 540attaggaaga tgatggcttg gatttcaatg gctgagttta tttttttttt ggtcgggagt 600tgaagtatcg ggaaaac 617
<210> 16
<211> 502
<212> DNA
<213> 人工序列
<220>
<223> 待用作终止子用于调控外源基因表达的序列
<400> 16ttgtacattt ggataagtca tttttcattg ctattttata agttacactt tgaattttat 60aataaatttt attttatttc aaggaccaga ttttataagg aaaccgctaa tctaactatc 120tttactcgta atttgtcatt tgagagctac ggagatcgtt gagtttacgt atgagtgttt 180agtctcacat taattatgaa tggtcaaaat gttaaattta taagagatgt aatctatata 240cctaatgcat taaaaatttg gatggagatg cgacgccccc cttttttgtg gtcctgaagt 300atagacttgt tgtcgcttct ggtgcactct catacttccc aacaaggaga aaaaactacc 360ataacaatta acaaactaac atttgttatt taaaaaaaca tacggatact gttttttccc 420catttattag gaagatgatg gcttggattt caatggctga gtttattttt tttttggtcg 480ggagttgaag tatcgggaaa ac 502
<210> 17
<211> 25
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 17gatattgatgttagactcaa gtggc 25
<210> 18
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 18cacysattcc acttcctwgg c 21
<210> 19
<211> 27
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 19ttgtcacatc agcacatccg tctttgc 27
<210> 20
<211> 27
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 20tcgccaagta tcttgtttga gcacttg 27
<210> 21
<211> 27
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 21agagcccggg agaagagagt gtgtttg 27
<210> 22
<211> 28
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 22ttctcccggg ggacgagagatggatggt 28
<210> 23
<211> 30
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 23ttctcccggg gttgaaacag gtgcaactga 30
<210> 24
<211> 28
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 24ttctcccggg taaccatctt tttcctca 28
<210> 25
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 25cacacttctt cactcacctc tcaa 24
<210> 26
<211> 21
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 26atctaggagg ggcagacatt g 21
<210> 27
<211> 24
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 27tcggtataaa gacttcgcgc tgat 24
<210> 28
<211> 27
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 28atgtcttcct tctcagtacg tttcctc 27
<210> 29
<211> 30
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 29caagttgatg catcaaggtg ggagcctaga 30
<210> 30
<211> 30
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 30agaagagctc agtatatagg tatttggtga 30
<210> 31
<211> 30
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 31agaagagctc ttgtacattt ggataagtca 30
<210> 32
<211> 30
<212> DNA
<213> 人工序列
<220>
<223> 待用作引物的序列
<400> 32agaagaattc gttttcccgatacttcaact 30
Claims (21)
1.一种调控外源基因在转基因生物中转录的方法,包括以下步骤:
a)用表达构建体制备转基因生物,其中所述构建体至少包含氮可诱导性启动子以及基因的开放阅读框架,其中,所述启动子具有选自SEQ ID NOS:1-13所示的序列和功能性片段及其衍生物,其中所述启动子与所述基因可操作地定位以表达所述基因。
2.权利要求1的方法,其进一步包括通过加入或去除氮诱导物调控所述基因转录性表达的步骤。
3.一种调控外源基因在转基因生物中转录的方法,包括:
a)制备表达构建体,其至少含有有或无顺式作用序列的氮可诱导性启动子、基因的开放阅读框架及在所述构建体3’末端的多聚腺苷酸化信号终止位点,其中所述启动子与所述基因可操作地定位以表达所述基因,并受氮诱导物的加入或去除之调控,用于所述基因的转录表达;
b)亚克隆步骤a)的构建体到所述生物的合适转染载体;
c)转移所述载体到所述生物或其细胞的DNA中;并且
d)在合适的培养基上选择转基因体。
4.权利要求3的方法,其中所述生物是植物。
5.权利要求4的方法,其进一步包括以下步骤:
e)将载体引入到合适的的根癌土壤杆菌株中;
f)使用步骤a)的土壤杆菌株将T-DNA转移到植物细胞;
g)在合适的培养基上选择所述植物细胞的转基因体;
h)从所述转基因细胞上再生胚或小植株;并且
i)从所述的再生胚生长为成熟植物体。
6.权利要求3的方法,其中顺式作用序列从苜蓿中表达的Nir基因之5’上游区域分离。
7.权利要求3的方法,其中启动子具有SEQ ID NOS:1-13所示的序列和功能性片段及其衍生物。
8.权利要求1的方法,其中生物选自植物、细菌、酵母和动物。
9.权利要求8的方法,其中植物是双子叶植物。
10.权利要求9的方法,其中双子叶植物是苜蓿或烟草。
11.权利要求2的方法,其中氮诱导物是硝酸盐。
12.权利要求3的方法,其中DNA转移方法是任一合适的转移方法,包括DNA轰击、电穿孔、PEG-介导的DNA转移和颈须噬菌体。
13.权利要求3的方法,其中表达构建体包含至少一种氮可诱导性启动子和至少一种顺式或反式作用元件。
14.权利要求3的方法,其中启动子或顺式作用序列从参与氮同化途径的任一基因的5’上游区域分离。
15.权利要求3的方法,其中启动子或顺式作用序列从其转录受氮源可得性来调控的任一基因的5’上游区域分离。
16.权利要求3的方法,其中启动子或顺式作用序列是其转录活性受在任何活生物环境中加入或去除任何氮源来调控的任何序列。
17.权利要求3的方法,从其中分离了启动子或顺式作用序列的生物是任何植物、真菌、酵母、细菌或动物。
18.一种启动外源基因在转基因生物中转录的启动子,包括有或无顺式作用序列的氮可诱导性启动子以表达所述基因,并且改造为可通过加入或去除氮诱导物来调控所述基因转录性表达。
19.权利要求18的启动子,其中所述启动子具有选自SEQ IDNOS:1-13所示的序列和功能性片段及其衍生物,
20.一种终止子,其与启动子联合以使用使外源基因在转基因生物中表达,其包括为在所述基因3’末端插入的多聚腺苷酸化信号终止位点,其中所述终止子与所述基因和所述启动子可操作地定位,由此允许所述基因表达。
21.权利要求19的终止子,其中所述终止子具有选自SEQ IDNOS:14-16所示的序列和功能性片段及其衍生物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15713399P | 1999-10-04 | 1999-10-04 | |
US60/157,133 | 1999-10-04 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1377419A true CN1377419A (zh) | 2002-10-30 |
CN100427603C CN100427603C (zh) | 2008-10-22 |
Family
ID=22562452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB008138680A Expired - Fee Related CN100427603C (zh) | 1999-10-04 | 2000-10-02 | 调控外源基因转录的方法 |
Country Status (15)
Country | Link |
---|---|
US (1) | US6420548B1 (zh) |
EP (1) | EP1222292B1 (zh) |
JP (1) | JP2003512821A (zh) |
KR (1) | KR100797667B1 (zh) |
CN (1) | CN100427603C (zh) |
AT (1) | ATE303445T1 (zh) |
AU (1) | AU782626B2 (zh) |
BR (1) | BR0014480A (zh) |
CA (1) | CA2385347C (zh) |
DE (1) | DE60022369T2 (zh) |
ES (1) | ES2248127T3 (zh) |
MX (1) | MXPA02003456A (zh) |
NZ (1) | NZ517906A (zh) |
PT (1) | PT1222292E (zh) |
WO (1) | WO2001025454A2 (zh) |
Families Citing this family (677)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790957B2 (en) | 2003-07-31 | 2010-09-07 | Honda Motor Co., Ltd. | Genes that confer regeneration ability to plants, and uses thereof |
MX2009008430A (es) | 2007-02-09 | 2009-10-28 | Genentech Inc | Anticuerpos anti-robo4 y sus usos. |
KR102467302B1 (ko) | 2007-09-26 | 2022-11-14 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
PT2610345E (pt) | 2007-11-27 | 2016-01-11 | Medicago Inc | Partículas semelhantes ao vírus (vlps) da gripe recombinantes produzidas em plantas transgénicas que expressam hemaglutinina |
TWI580694B (zh) | 2007-11-30 | 2017-05-01 | 建南德克公司 | 抗-vegf抗體 |
KR101956910B1 (ko) | 2008-01-21 | 2019-03-12 | 메디카고 인코포레이티드 | 헤마글루티닌을 발현하는 트랜스제닉 식물에서 생산된 재조합 인플루엔자 바이러스-유사 입자(VLPs) |
CN112481367A (zh) * | 2008-03-31 | 2021-03-12 | 健泰科生物技术公司 | 用于治疗和诊断哮喘的组合物和方法 |
WO2010078376A2 (en) | 2008-12-30 | 2010-07-08 | Ventana Medical Systems, Inc. | Fc-specific polymer-conjugated antibodies and their diagnostic use |
MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
PT2417156E (pt) | 2009-04-07 | 2015-04-29 | Roche Glycart Ag | Anticorpos trivalentes, biespecíficos |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
DK2445928T3 (en) | 2009-06-24 | 2018-05-28 | Medicago Inc | CHEMICAL INFLUENZA VIRUS-LIKE PARTICLES INCLUDING HEMAGGLUTIN |
US9321823B2 (en) | 2009-09-02 | 2016-04-26 | Genentech, Inc. | Mutant smoothened and methods of using the same |
SG179196A1 (en) | 2009-09-16 | 2012-04-27 | Genentech Inc | Coiled coil and/or tether containing protein complexes and uses thereof |
EP2509626B1 (en) | 2009-12-11 | 2016-02-10 | F.Hoffmann-La Roche Ag | Anti-vegf-c antibodies and methods using same |
TWI623323B (zh) | 2009-12-21 | 2018-05-11 | 建南德克公司 | 抗體調配物 |
MX2012008958A (es) | 2010-02-18 | 2012-08-23 | Genentech Inc | Antagonista de neurogulina y usos de los mismos para el tratamiento contra el cancer. |
US8846041B2 (en) | 2010-03-24 | 2014-09-30 | Genentech, Inc. | Anti-LRP6 antibodies |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
WO2011147834A1 (en) | 2010-05-26 | 2011-12-01 | Roche Glycart Ag | Antibodies against cd19 and uses thereof |
JP5940061B2 (ja) | 2010-06-18 | 2016-06-29 | ジェネンテック, インコーポレイテッド | 抗axl抗体及び使用方法 |
WO2011161119A1 (en) | 2010-06-22 | 2011-12-29 | F. Hoffmann-La Roche Ag | Antibodies against insulin-like growth factor i receptor and uses thereof |
WO2011161189A1 (en) | 2010-06-24 | 2011-12-29 | F. Hoffmann-La Roche Ag | Anti-hepsin antibodies and methods of use |
CA2803792A1 (en) | 2010-07-09 | 2012-01-12 | Genentech, Inc. | Anti-neuropilin antibodies and methods of use |
AR082163A1 (es) | 2010-07-15 | 2012-11-14 | Hoffmann La Roche | Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
CA2805564A1 (en) | 2010-08-05 | 2012-02-09 | Stefan Jenewein | Anti-mhc antibody anti-viral cytokine fusion protein |
CA2806640A1 (en) | 2010-08-13 | 2012-02-16 | Roche Glycart Ag | Anti-tenascin-c a2 antibodies and methods of use |
NO2603530T3 (zh) | 2010-08-13 | 2018-04-07 | ||
JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ジスルフィドによって安定化されたFv断片を含む二重特異性抗体 |
TW201215405A (en) | 2010-08-25 | 2012-04-16 | Hoffmann La Roche | Antibodies against IL-18R1 and uses thereof |
WO2012047968A2 (en) | 2010-10-05 | 2012-04-12 | Genentech, Inc. | Mutant smoothened and methods of using the same |
TW201300417A (zh) | 2010-11-10 | 2013-01-01 | Genentech Inc | 用於神經疾病免疫療法之方法及組合物 |
KR101615474B1 (ko) | 2010-12-16 | 2016-04-25 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
MA34881B1 (fr) | 2010-12-20 | 2014-02-01 | Genentech Inc | Anticorps et immunoconjugués anti-mésothéline |
MA34818B1 (fr) | 2010-12-22 | 2014-01-02 | Genentech Inc | Anticorps anti-pcsk9 et procédés d'utilisation |
WO2012085111A1 (en) | 2010-12-23 | 2012-06-28 | F. Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
WO2012093068A1 (en) | 2011-01-03 | 2012-07-12 | F. Hoffmann-La Roche Ag | A pharmaceutical composition of a complex of an anti-dig antibody and digoxigenin that is conjugated to a peptide |
CN105440123B (zh) | 2011-02-10 | 2020-10-09 | 罗切格利卡特公司 | 突变体白介素-2多肽 |
KR20130118941A (ko) | 2011-02-10 | 2013-10-30 | 로슈 글리카트 아게 | 면역치료법 |
CN103502271B (zh) | 2011-02-28 | 2016-10-26 | 霍夫曼-拉罗奇有限公司 | 抗原结合蛋白 |
CA2824824A1 (en) | 2011-02-28 | 2012-09-07 | F. Hoffmann-La Roche Ag | Monovalent antigen binding proteins |
ES2692268T3 (es) | 2011-03-29 | 2018-12-03 | Roche Glycart Ag | Variantes de Fc de anticuerpo |
CN103596983B (zh) | 2011-04-07 | 2016-10-26 | 霍夫曼-拉罗奇有限公司 | 抗fgfr4抗体及使用方法 |
AU2012244816B2 (en) | 2011-04-20 | 2015-12-10 | Roche Glycart Ag | Method and constructs for the pH dependent passage of the blood-brain-barrier |
WO2012146630A1 (en) | 2011-04-29 | 2012-11-01 | F. Hoffmann-La Roche Ag | N-terminal acylated polypeptides, methods for their production and uses thereof |
EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
JP5987053B2 (ja) | 2011-05-12 | 2016-09-06 | ジェネンテック, インコーポレイテッド | フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングlc−ms/ms法 |
BR112013026266A2 (pt) | 2011-05-16 | 2020-11-10 | Genentech, Inc | método de tratamento, anticorpos isolado e anti-fgfr1, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de diabetes em um indivíduo |
BR112013032235A2 (pt) | 2011-06-15 | 2016-11-22 | Hoffmann La Roche | anticorpos do receptor de epo anti-humano e métodos de uso |
ES2667864T3 (es) | 2011-06-22 | 2018-05-14 | F. Hoffmann-La Roche Ag | Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I |
SG194932A1 (en) | 2011-06-30 | 2013-12-30 | Genentech Inc | Anti-c-met antibody formulations |
MX2014001766A (es) | 2011-08-17 | 2014-05-01 | Genentech Inc | Anticuerpos de neuregulina y sus usos. |
WO2013026832A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Anti-mcsp antibodies |
US20130078250A1 (en) | 2011-08-23 | 2013-03-28 | Oliver Ast | Bispecific t cell activating antigen binding molecules |
EP2748202B1 (en) | 2011-08-23 | 2018-07-04 | Roche Glycart AG | Bispecific antigen binding molecules |
RU2617970C2 (ru) | 2011-08-23 | 2017-04-28 | Рош Гликарт Аг | Антитела, не содержащие fc-фрагмента, включающие два fab-фрагмента, и способы их применения |
ES2857734T3 (es) | 2011-08-23 | 2021-09-29 | Roche Glycart Ag | Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas |
JP6159724B2 (ja) | 2011-08-23 | 2017-07-05 | ロシュ グリクアート アーゲー | T細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法 |
RU2014109395A (ru) | 2011-09-15 | 2015-10-20 | Дженентек, Инк. | Способы стимуляции дифференциации |
MX2014002996A (es) | 2011-09-23 | 2014-05-28 | Roche Glycart Ag | Anticuerpos anti - egfr/anti - igf-1r bisespecificos. |
MX2014004074A (es) | 2011-10-05 | 2014-06-05 | Genentech Inc | Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2. |
EP3461839A1 (en) | 2011-10-14 | 2019-04-03 | F. Hoffmann-La Roche AG | Anti-htra1 antibodies and methods of use |
JP6254087B2 (ja) | 2011-10-15 | 2017-12-27 | ジェネンテック, インコーポレイテッド | 癌を治療するためのscd1アンタゴニスト |
WO2013059531A1 (en) | 2011-10-20 | 2013-04-25 | Genentech, Inc. | Anti-gcgr antibodies and uses thereof |
BR112014010009A2 (pt) | 2011-10-26 | 2017-04-25 | Univ California | "anticorpo que se liga a cd44, seus métodos de produção e usos no tratamento ou prevenção de malignidade hematológica ou leucemia linfocítica crônica, método de alvejar anticorpo, kit de detecção, bem como composição farmacêutica, molécula de ácido nucleico e vetor de expressão" |
CN104039340B (zh) | 2011-10-28 | 2017-04-05 | 霍夫曼-拉罗奇有限公司 | 治疗黑素瘤的方法及治疗剂组合 |
FI3091029T3 (fi) | 2011-10-31 | 2023-03-20 | Hoffmann La Roche | Anti-il13-vasta-aineformulaatioita |
AU2012340826A1 (en) | 2011-11-21 | 2014-05-29 | Genentech, Inc. | Purification of anti-c-met antibodies |
CA2854042A1 (en) | 2011-11-29 | 2013-06-06 | Genentech, Inc. | Compositions and methods for prostate cancer analysis |
US20140335084A1 (en) | 2011-12-06 | 2014-11-13 | Hoffmann-La Roche Inc. | Antibody formulation |
MX2014007262A (es) | 2011-12-22 | 2014-08-01 | Hoffmann La Roche | Sistema de exhibicion de anticuerpos de longitud completa para celulas eucarioticas y su uso. |
ES2791758T3 (es) | 2011-12-22 | 2020-11-05 | Hoffmann La Roche | Organización de vectores de expresión, procedimientos de generación de células de producción novedosos y su uso para la producción recombinante de polipéptidos |
MX355624B (es) | 2011-12-22 | 2018-04-25 | Hoffmann La Roche | Combinaciones de elementos de vector de expresion, metodos novedosos de generacion de celulas de produccion y su uso para la produccion recombinante de polipeptidos. |
AR089434A1 (es) | 2011-12-23 | 2014-08-20 | Genentech Inc | Procedimiento para preparar formulaciones con alta concentracion de proteinas |
JP2015509091A (ja) | 2012-01-09 | 2015-03-26 | ザ スクリプス リサーチ インスティテュート | ヒト化抗体 |
CA2863224A1 (en) | 2012-01-09 | 2013-07-18 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
CN104066449B (zh) | 2012-01-18 | 2018-04-27 | 霍夫曼-拉罗奇有限公司 | 抗lrp5抗体及使用方法 |
EP2804630B1 (en) | 2012-01-18 | 2017-10-18 | F. Hoffmann-La Roche AG | Methods of using fgf19 modulators |
MX2014009565A (es) | 2012-02-10 | 2014-11-10 | Genentech Inc | Anticuerpos monocatenarios y otros heteromultimeros. |
US20130209473A1 (en) | 2012-02-11 | 2013-08-15 | Genentech, Inc. | R-spondin translocations and methods using the same |
WO2013120929A1 (en) | 2012-02-15 | 2013-08-22 | F. Hoffmann-La Roche Ag | Fc-receptor based affinity chromatography |
JP5859148B2 (ja) | 2012-03-08 | 2016-02-10 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Aβ抗体製剤 |
CN104220457A (zh) | 2012-03-27 | 2014-12-17 | 霍夫曼-拉罗奇有限公司 | 涉及her3抑制剂的诊断和治疗 |
RU2014143251A (ru) | 2012-03-28 | 2016-05-20 | Дженентек, Инк. | Антиидиотипические антитела к hcmv и их применение |
AR090549A1 (es) | 2012-03-30 | 2014-11-19 | Genentech Inc | Anticuerpos anti-lgr5 e inmunoconjugados |
CN104245937B (zh) | 2012-04-17 | 2021-09-21 | 弗·哈夫曼-拉罗切有限公司 | 使用修饰的核酸表达多肽的方法 |
RU2014148162A (ru) | 2012-05-01 | 2016-06-20 | Дженентек, Инк. | Анти-pmel17 антитела и их иммуноконъюгаты |
WO2013170191A1 (en) | 2012-05-11 | 2013-11-14 | Genentech, Inc. | Methods of using antagonists of nad biosynthesis from nicotinamide |
KR101843614B1 (ko) | 2012-05-23 | 2018-03-29 | 제넨테크, 인크. | 치료제의 선택 방법 |
RU2015101113A (ru) | 2012-06-15 | 2016-08-10 | Дженентек, Инк. | Антитела против pcsk9, составы, дозы и способы применения |
CN104582736A (zh) | 2012-06-21 | 2015-04-29 | 印第安纳大学研究及科技有限公司 | Fc效应子功能改变的肠降血糖素受体配体多肽Fc区融合多肽和缀合物 |
CA2871386A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof |
BR112014032193A2 (pt) | 2012-06-27 | 2017-06-27 | Hoffmann La Roche | métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
JP6247287B2 (ja) | 2012-07-04 | 2017-12-13 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗ビオチン抗体および使用方法 |
CN107082810B (zh) | 2012-07-04 | 2020-12-25 | 弗·哈夫曼-拉罗切有限公司 | 抗茶碱抗体及使用方法 |
KR102090849B1 (ko) | 2012-07-04 | 2020-03-19 | 에프. 호프만-라 로슈 아게 | 공유 결합된 항원-항체 접합체 |
CA2877009C (en) | 2012-07-05 | 2023-10-03 | Devin TESAR | Expression and secretion system |
JP6297550B2 (ja) | 2012-07-09 | 2018-03-20 | ジェネンテック, インコーポレイテッド | 抗cd79b抗体を含む免疫複合体 |
EP2869849A1 (en) | 2012-07-09 | 2015-05-13 | Genentech, Inc. | Immunoconjugates comprising anti-cd22 antibodies |
BR112015000439A2 (pt) | 2012-07-09 | 2017-12-19 | Genentech Inc | imunoconjugado , formulação farmacêutica e métodos de tratamento de um indivíduo e de inibição da proliferação |
AR091700A1 (es) | 2012-07-09 | 2015-02-25 | Genentech Inc | Anticuerpos e inmunoconjugados anti-cd79b |
EP3495387B1 (en) | 2012-07-13 | 2021-09-01 | Roche Glycart AG | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases |
PL2880170T3 (pl) | 2012-08-02 | 2017-02-28 | F.Hoffmann-La Roche Ag | SPOSÓB WYTWARZANIA ROZPUSZCZALNEGO FcR JAKO FUZJI Fc Z OBOJĘTNYM REGIONEM Fc IMMUNOGLOBULINY I JEGO ZASTOSOWANIA |
JP6290209B2 (ja) | 2012-08-07 | 2018-03-07 | ロシュ グリクアート アーゲー | 低下した及び増加したエフェクター機能を有するように操作された2つの抗体を含む組成物。 |
MA20150232A1 (fr) | 2012-08-08 | 2015-07-31 | Roche Glycart Ag | Protéines de fusion de l'interleukine-10 et leurs utilisations |
CA2878626A1 (en) | 2012-08-09 | 2014-02-13 | Roche Glycart Ag | Asgpr antibodies and uses thereof |
US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
CA2879768A1 (en) | 2012-10-08 | 2014-04-17 | Roche Glycart Ag | Fc-free antibodies comprising two fab-fragments and methods of use |
CN104755500B (zh) | 2012-11-08 | 2020-10-02 | 霍夫曼-拉罗奇有限公司 | 结合HER3 β-发夹的HER3抗原结合蛋白 |
CN104968367B (zh) | 2012-11-13 | 2018-04-13 | 弗·哈夫曼-拉罗切有限公司 | 抗血凝素抗体和使用方法 |
MX361076B (es) | 2012-12-21 | 2018-11-27 | Hoffmann La Roche | Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro. |
WO2014107739A1 (en) | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
WO2014116749A1 (en) | 2013-01-23 | 2014-07-31 | Genentech, Inc. | Anti-hcv antibodies and methods of using thereof |
EP3708584A1 (en) | 2013-02-26 | 2020-09-16 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
RU2015140917A (ru) | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Биспецифические антигенсвязывающие молекулы, активирующие т-клетки |
EP2961773B1 (en) | 2013-02-26 | 2019-03-20 | Roche Glycart AG | Bispecific t cell activating antigen binding molecules |
RU2015140921A (ru) | 2013-02-26 | 2017-04-03 | Роше Гликарт Аг | Антитела к mcsp |
AR095399A1 (es) | 2013-03-13 | 2015-10-14 | Genentech Inc | Formulaciones con oxidación reducida, método |
CA2904169C (en) | 2013-03-13 | 2021-12-07 | Genentech, Inc. | Formulations with reduced oxidation |
US20140314778A1 (en) | 2013-03-13 | 2014-10-23 | Genentech, Inc. | Formulations with reduced oxidation |
ES2688895T3 (es) | 2013-03-13 | 2018-11-07 | F. Hoffmann-La Roche Ag | Formulaciones con oxidación reducida |
CA2906057A1 (en) | 2013-03-13 | 2014-10-02 | Genentech, Inc. | Antibody formulations |
US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
WO2014159835A1 (en) | 2013-03-14 | 2014-10-02 | Genentech, Inc. | Anti-b7-h4 antibodies and immunoconjugates |
JP2016515132A (ja) | 2013-03-14 | 2016-05-26 | ジェネンテック, インコーポレイテッド | Mek阻害剤化合物のher3/egfr阻害剤化合物との組み合わせ及び使用方法 |
EP2970476A1 (en) | 2013-03-15 | 2016-01-20 | F. Hoffmann-La Roche AG | Compositions and methods for diagnosis and treatment of hepatic cancers |
US20140328849A1 (en) | 2013-03-15 | 2014-11-06 | Genentech, Inc. | Anti-crth2 antibodies and methods of use |
EP3712252A1 (en) | 2013-03-15 | 2020-09-23 | F. Hoffmann-La Roche AG | Cell culture compositions with antioxidants and methods for polypeptide production |
JP6456356B2 (ja) | 2013-03-15 | 2019-01-23 | ジェネンテック, インコーポレイテッド | IL−22ポリペプチド及びIL−22Fc融合タンパク質並びに使用方法 |
WO2014150877A2 (en) | 2013-03-15 | 2014-09-25 | Ac Immune S.A. | Anti-tau antibodies and methods of use |
KR102202476B1 (ko) | 2013-03-15 | 2021-01-12 | 제넨테크, 인크. | 세포 배양 배지 및 항체 생산 방법 |
UA118028C2 (uk) | 2013-04-03 | 2018-11-12 | Рош Глікарт Аг | Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування |
US20160053023A1 (en) | 2013-04-09 | 2016-02-25 | Annexon, Inc. | Methods of treatment for neuromyelitis optica |
EP3878866A1 (en) | 2013-04-29 | 2021-09-15 | F. Hoffmann-La Roche AG | Fc-receptor binding modified asymmetric antibodies and methods of use |
WO2014177460A1 (en) | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
SG10201810481UA (en) | 2013-04-29 | 2018-12-28 | Hoffmann La Roche | Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases |
SG11201509566RA (en) | 2013-05-20 | 2015-12-30 | Genentech Inc | Anti-transferrin receptor antibodies and methods of use |
SG10201710758PA (en) | 2013-07-09 | 2018-02-27 | Annexon Inc | Anti-complement factor c1q antibodies and uses thereof |
WO2015017146A2 (en) | 2013-07-18 | 2015-02-05 | Fabrus, Inc. | Antibodies with ultralong complementarity determining regions |
EP3022221B1 (en) | 2013-07-18 | 2021-09-15 | Taurus Biosciences, LLC | Humanized antibodies with ultralong complementarity determining regions |
EP2832854A1 (en) | 2013-08-02 | 2015-02-04 | F. Hoffmann-La Roche AG | Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin |
US10442836B2 (en) | 2013-08-12 | 2019-10-15 | Genentech, Inc. | 1-(chloromethyl)-2,3-dihydro-1H-benzo[E]indole dimer antibody-drug conjugate compounds, and methods of use and treatment |
EP3046940B1 (en) | 2013-09-17 | 2019-07-03 | F.Hoffmann-La Roche Ag | Methods of using anti-lgr5 antibodies |
EP3049437A1 (en) | 2013-09-27 | 2016-08-03 | F. Hoffmann-La Roche AG | Thermus thermophilus slyd fkbp domain specific antibodies |
PE20160541A1 (es) | 2013-09-27 | 2016-06-03 | Genentech Inc | Formulaciones de anticuerpos anti-pdl1 |
JP6422956B2 (ja) | 2013-10-11 | 2018-11-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性ドメイン交換共通可変軽鎖抗体 |
BR112016007635A2 (pt) | 2013-10-11 | 2017-09-12 | Genentech Inc | inibidores de nsp4 e métodos de uso |
KR20160070136A (ko) | 2013-10-18 | 2016-06-17 | 제넨테크, 인크. | 항-rspo2 및/또는 항-rspo3 항체 및 그의 용도 |
CA2924873A1 (en) | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
AU2014348552A1 (en) | 2013-11-13 | 2016-06-02 | Zymeworks Inc. | Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof |
EP3783020A1 (en) | 2013-11-21 | 2021-02-24 | F. Hoffmann-La Roche AG | Anti-alpha-synuclein antibodies and methods of use |
CA2931356A1 (en) | 2013-11-27 | 2015-06-04 | Zymeworks Inc. | Bispecific antigen-binding constructs targeting her2 |
SG11201604784XA (en) | 2013-12-13 | 2016-07-28 | Genentech Inc | Anti-cd33 antibodies and immunoconjugates |
CN104711260B (zh) * | 2013-12-13 | 2017-07-07 | 华中农业大学 | 水稻缺氮后恢复供氮特异诱导表达的启动子y8a及应用 |
MX2016007578A (es) | 2013-12-16 | 2016-10-03 | Genentech Inc | Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento. |
RU2016128726A (ru) | 2013-12-17 | 2018-01-23 | Дженентек, Инк. | Способы лечения злокачественных опухолей с использованием антагонистов связывания по оси pd-1 и антитела против cd20 |
EP3083686B2 (en) | 2013-12-17 | 2023-03-22 | F. Hoffmann-La Roche AG | Methods of treating cancers using pd-1 axis binding antagonists and taxanes |
BR112016013963A2 (pt) | 2013-12-17 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 |
US10137170B2 (en) | 2013-12-20 | 2018-11-27 | Indiana University Research And Technology Corporation | Lipidated incretin receptor ligand human immunoglobulin Fc-region fusion polypeptides |
CR20160270A (es) | 2013-12-20 | 2016-09-05 | Hoffmann La Roche | ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN |
TWI728373B (zh) | 2013-12-23 | 2021-05-21 | 美商建南德克公司 | 抗體及使用方法 |
MX2016008189A (es) | 2014-01-03 | 2016-09-29 | Hoffmann La Roche | Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos. |
MX2016008191A (es) | 2014-01-03 | 2017-11-16 | Hoffmann La Roche | Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente. |
US10561737B2 (en) | 2014-01-03 | 2020-02-18 | Hoffmann-La Roche Inc. | Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles |
CN111057147B (zh) | 2014-01-06 | 2023-11-10 | 豪夫迈·罗氏有限公司 | 单价血脑屏障穿梭模块 |
KR20160107190A (ko) | 2014-01-15 | 2016-09-13 | 에프. 호프만-라 로슈 아게 | 변형된 FcRn-결합 및 유지된 단백질 A-결합 성질을 갖는 Fc-영역 변이체 |
AU2015209154A1 (en) | 2014-01-24 | 2017-02-16 | Genentech, Inc. | Methods of using anti-STEAP1 antibodies and immunoconjugates |
JP6736467B2 (ja) | 2014-02-04 | 2020-08-05 | ジェネンテック, インコーポレイテッド | 平滑化変異体及びその使用方法 |
EP3102595B1 (en) | 2014-02-06 | 2018-11-07 | F.Hoffmann-La Roche Ag | Interleukin-2 fusion proteins and uses thereof |
TWI705824B (zh) | 2014-02-08 | 2020-10-01 | 美商建南德克公司 | 治療阿茲海默症之方法 |
TW202239429A (zh) | 2014-02-08 | 2022-10-16 | 美商建南德克公司 | 治療阿茲海默症之方法 |
ES2685424T3 (es) | 2014-02-12 | 2018-10-09 | F. Hoffmann-La Roche Ag | Anticuerpos anti-Jagged1 y procedimientos de uso |
MX2016010729A (es) | 2014-02-21 | 2016-10-26 | Genentech Inc | Anticuerpos biespecificos anti-il-13 / il-17 y sus usos. |
US20170107294A1 (en) | 2014-03-21 | 2017-04-20 | Nordlandssykehuset Hf | Anti-cd14 antibodies and uses thereof |
CN106414552B (zh) | 2014-03-25 | 2020-08-25 | 豪夫迈·罗氏有限公司 | 制备用于细胞培养基中的泊洛沙姆的方法 |
SG11201608106PA (en) | 2014-03-31 | 2016-10-28 | Genentech Inc | Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists |
PE20211291A1 (es) | 2014-03-31 | 2021-07-20 | Genentech Inc | Anticuerpos anti-ox40 y metodos de uso |
EP3126389A1 (en) | 2014-04-02 | 2017-02-08 | F. Hoffmann-La Roche AG | Method for detecting multispecific antibody light chain mispairing |
WO2015164615A1 (en) | 2014-04-24 | 2015-10-29 | University Of Oslo | Anti-gluten antibodies and uses thereof |
JP2017522861A (ja) | 2014-05-22 | 2017-08-17 | ジェネンテック, インコーポレイテッド | 抗gpc3抗体及びイムノコンジュゲート |
KR20170005016A (ko) | 2014-05-23 | 2017-01-11 | 제넨테크, 인크. | MiT 바이오마커 및 그의 사용 방법 |
CN106459202A (zh) | 2014-06-11 | 2017-02-22 | 豪夫迈·罗氏有限公司 | 抗LgR5抗体及其用途 |
EP3164419A1 (en) | 2014-06-26 | 2017-05-10 | F. Hoffmann-La Roche AG | Anti-brdu antibodies and methods of use |
AR100978A1 (es) | 2014-06-26 | 2016-11-16 | Hoffmann La Roche | LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS |
EP3166627A1 (en) | 2014-07-11 | 2017-05-17 | Genentech, Inc. | Notch pathway inhibition |
DK3309174T3 (da) | 2014-07-11 | 2022-06-07 | Ventana Med Syst Inc | ANTI-PD-L1-antistoffer og diagnostiske anvendelser deraf |
CA2951599A1 (en) | 2014-08-04 | 2016-02-11 | F. Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
SG10201913611QA (en) | 2014-08-08 | 2020-03-30 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
TW201625689A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 抗-b7-h4抗體及免疫結合物 |
MX2017003126A (es) | 2014-09-12 | 2017-08-28 | Genentech Inc | Anticuerpos anti-her2 e inmunoconjugados. |
MX2017003022A (es) | 2014-09-12 | 2017-05-12 | Genentech Inc | Anticuerpos anti-cll-1 e inmunoconjugados. |
WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
BR112017004393A2 (pt) | 2014-09-15 | 2018-02-27 | Genentech Inc | formulações de anticorpo |
CN107124870A (zh) | 2014-09-17 | 2017-09-01 | 基因泰克公司 | 包含抗her2抗体和吡咯并苯并二氮杂*的免疫缀合物 |
DK3262071T3 (da) | 2014-09-23 | 2020-06-15 | Hoffmann La Roche | Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater |
WO2016061389A2 (en) | 2014-10-16 | 2016-04-21 | Genentech, Inc. | Anti-alpha-synuclein antibodies and methods of use |
RU2017119231A (ru) | 2014-11-03 | 2018-12-06 | Дженентек, Инк. | Способы и биомаркеры для прогнозирования эффективности и оценки лечения агонистом ох40 |
RU2017119009A (ru) | 2014-11-03 | 2018-12-05 | Дженентек, Инк. | Анализы для обнаружения субпопуляций иммунных т-клеток и способы их применения |
US10316081B2 (en) | 2014-11-05 | 2019-06-11 | Annexon, Inc. | Humanized anti-complement factor C1Q antibodies |
PT3215528T (pt) | 2014-11-06 | 2019-10-11 | Hoffmann La Roche | Variantes da região fc com ligação modificada ao fcrn e métodos de utilização |
WO2016071377A1 (en) | 2014-11-06 | 2016-05-12 | F. Hoffmann-La Roche Ag | Fc-region variants with modified fcrn- and protein a-binding properties |
WO2016073157A1 (en) | 2014-11-06 | 2016-05-12 | Genentech, Inc. | Anti-ang2 antibodies and methods of use thereof |
TWI705976B (zh) | 2014-11-10 | 2020-10-01 | 美商建南德克公司 | 抗介白素-33抗體及其用途 |
WO2016077369A1 (en) | 2014-11-10 | 2016-05-19 | Genentech, Inc. | Animal model for nephropathy and agents for treating the same |
KR102588377B1 (ko) | 2014-11-14 | 2023-10-12 | 에프. 호프만-라 로슈 아게 | Tnf 계열 리간드 삼량체를 포함하는 항원 결합 분자 |
WO2016081384A1 (en) | 2014-11-17 | 2016-05-26 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
EP3221361B1 (en) | 2014-11-19 | 2021-04-21 | Genentech, Inc. | Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use |
WO2016081639A1 (en) | 2014-11-19 | 2016-05-26 | Genentech, Inc. | Antibodies against bace1 and use thereof for neural disease immunotherapy |
CN107001473B (zh) | 2014-11-19 | 2021-07-09 | 豪夫迈·罗氏有限公司 | 抗-运铁蛋白受体抗体及使用方法 |
CN107207609B (zh) | 2014-11-20 | 2022-07-19 | 豪夫迈·罗氏有限公司 | 共同轻链和使用方法 |
DK3221355T3 (da) | 2014-11-20 | 2020-12-07 | Hoffmann La Roche | Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister |
CA2968258A1 (en) | 2014-11-27 | 2016-06-02 | Zymeworks Inc. | Methods of using bispecific antigen-binding constructs targeting her2 |
JP6721590B2 (ja) | 2014-12-03 | 2020-07-15 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 多重特異性抗体 |
JP6802158B2 (ja) | 2014-12-05 | 2020-12-16 | ジェネンテック, インコーポレイテッド | 抗CD79b抗体及び使用方法 |
AU2015360579A1 (en) | 2014-12-10 | 2017-05-18 | Genentech, Inc. | Blood brain barrier receptor antibodies and methods of use |
CA2966287A1 (en) | 2014-12-17 | 2016-06-23 | F. Hoffmann-La Roche Ag | Novel methods for enzyme mediated polypeptide conjugation using sortase |
BR112017011170A2 (pt) | 2014-12-18 | 2018-02-27 | Hoffmann La Roche | método para determinar a citotoxicidade dependente do complemento de uma composição |
ES2899894T3 (es) | 2014-12-19 | 2022-03-15 | Chugai Pharmaceutical Co Ltd | Anticuerpos anti-C5 y métodos de uso |
CN107428823B (zh) | 2015-01-22 | 2021-10-26 | 中外制药株式会社 | 两种以上抗-c5抗体的组合与使用方法 |
WO2016126972A1 (en) | 2015-02-04 | 2016-08-11 | Genentech, Inc. | Mutant smoothened and methods of using the same |
EA201791754A1 (ru) | 2015-02-05 | 2019-01-31 | Чугаи Сейяку Кабусики Кайся | АНТИТЕЛА, СОДЕРЖАЩИЕ ЗАВИСЯЩИЙ ОТ КОНЦЕНТРАЦИИ ИОНОВ АНТИГЕНСВЯЗЫВАЮЩИЙ ДОМЕН, ВАРИАНТЫ Fc-ОБЛАСТИ, IL-8-СВЯЗЫВАЮЩИЕ АНТИТЕЛА И ИХ ПРИМЕНЕНИЯ |
KR20170127011A (ko) | 2015-03-16 | 2017-11-20 | 제넨테크, 인크. | Il-13을 검출 및 정량화하는 방법 및 th2-연관 질환의 진단 및 치료에서의 용도 |
WO2016146833A1 (en) | 2015-03-19 | 2016-09-22 | F. Hoffmann-La Roche Ag | Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance |
MX2017012802A (es) | 2015-04-07 | 2018-04-11 | Alector Llc | Anticuerpos antisortilina y métodos para su uso. |
WO2016166348A1 (en) | 2015-04-17 | 2016-10-20 | Elsalys Biotech | Anti-tyro3 antibodies and uses thereof |
CN108064343B (zh) | 2015-04-21 | 2021-07-09 | 基因泰克公司 | 用于前列腺癌分析的组合物和方法 |
CN107810197B (zh) | 2015-04-24 | 2022-10-25 | 豪夫迈·罗氏有限公司 | 鉴定包含结合多肽的细菌的方法 |
CN107709363A (zh) | 2015-05-01 | 2018-02-16 | 基因泰克公司 | 掩蔽抗cd3抗体和使用方法 |
US20160346387A1 (en) | 2015-05-11 | 2016-12-01 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
WO2016196343A1 (en) | 2015-05-29 | 2016-12-08 | Genentech, Inc. | Humanized anti-ebola virus glycoprotein antibodies and methods of use |
PL3303619T3 (pl) | 2015-05-29 | 2020-10-05 | F. Hoffmann-La Roche Ag | Metylacja promotora PD-L1 w chorobach nowotworowych |
JP2018516933A (ja) | 2015-06-02 | 2018-06-28 | ジェネンテック, インコーポレイテッド | 抗il−34抗体を使用して神経学的疾患を治療するための組成物及び方法 |
UA126272C2 (uk) | 2015-06-05 | 2022-09-14 | Дженентек, Інк. | Антитіло проти тау-білка та спосіб його застосування |
MX2017015937A (es) | 2015-06-08 | 2018-12-11 | Genentech Inc | Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1. |
WO2016200836A1 (en) | 2015-06-08 | 2016-12-15 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies |
EP3307771A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
EP3307779A2 (en) | 2015-06-12 | 2018-04-18 | Alector LLC | Anti-cd33 antibodies and methods of use thereof |
WO2016205176A1 (en) | 2015-06-15 | 2016-12-22 | Genentech, Inc. | Antibodies and immunoconjugates |
EP3916018A1 (en) | 2015-06-16 | 2021-12-01 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
AU2016280102B2 (en) | 2015-06-16 | 2022-06-16 | Genentech, Inc. | Humanized and affinity matured antibodies to FcRH5 and methods of use |
EP3310378B1 (en) | 2015-06-16 | 2024-01-24 | F. Hoffmann-La Roche AG | Anti-cll-1 antibodies and methods of use |
CA2986263A1 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes |
WO2016205531A2 (en) | 2015-06-17 | 2016-12-22 | Genentech, Inc. | Anti-her2 antibodies and methods of use |
CN113929779A (zh) | 2015-06-24 | 2022-01-14 | 豪夫迈·罗氏有限公司 | 人源化的抗-Tau(pS422)抗体和使用方法 |
BR112017024610A2 (pt) | 2015-06-24 | 2018-07-31 | F. Hoffmann-La Roche Ag | anticorpos para receptor antitransferrina com afinidade especificada |
AU2016288461B2 (en) | 2015-06-29 | 2021-10-07 | Ventana Medical Systems, Inc. | Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin |
CA2989936A1 (en) | 2015-06-29 | 2017-01-05 | Genentech, Inc. | Type ii anti-cd20 antibody for use in organ transplantation |
ES2699526T3 (es) | 2015-07-28 | 2019-02-11 | Hoffmann La Roche | Prueba de endotoxinas bacterianas mejorada para la determinación de endotoxinas |
TW202330904A (zh) | 2015-08-04 | 2023-08-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
CN115960235A (zh) | 2015-08-28 | 2023-04-14 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
EP3350202A1 (en) | 2015-09-18 | 2018-07-25 | Chugai Seiyaku Kabushiki Kaisha | Il-8-binding antibodies and uses thereof |
EP3353206A1 (en) | 2015-09-22 | 2018-08-01 | Spring Bioscience Corporation | Anti-ox40 antibodies and diagnostic uses thereof |
WO2017053807A2 (en) | 2015-09-23 | 2017-03-30 | Genentech, Inc. | Optimized variants of anti-vegf antibodies |
BR112018005931A2 (pt) | 2015-09-24 | 2018-10-09 | Abvitro Llc | composições de anticorpo para hiv e métodos de uso |
EP3353310B1 (en) | 2015-09-25 | 2020-04-29 | H. Hoffnabb-La Roche Ag | Process for producing thioesters employing a sortase a |
JP6998862B2 (ja) | 2015-09-25 | 2022-02-04 | エフ.ホフマン-ラ ロシュ アーゲー | 可溶性ソルターゼa |
BR112018003594A2 (pt) | 2015-09-25 | 2018-09-25 | Hoffmann La Roche | cadeia pesada de imunoglobulina recombinante, anticorpos, método de produção de conjugado e conjugados |
RU2732591C2 (ru) | 2015-09-25 | 2020-09-21 | Дженентек, Инк. | Анти-tigit антитела и способы применения |
EP3353314A1 (en) | 2015-09-25 | 2018-08-01 | H. Hoffnabb-La Roche Ag | Transamidation employing sortase a in deep eutectic solvents |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
CN108026177B (zh) | 2015-10-02 | 2021-11-26 | 豪夫迈·罗氏有限公司 | 双特异性抗cd19xcd3 t细胞活化性抗原结合分子 |
WO2017055393A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules |
RU2753390C1 (ru) | 2015-10-02 | 2021-08-13 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела к человеческому cd20/человеческому рецептору трансферрина и способы их применения |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
MA43345A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation |
AU2016329120B2 (en) | 2015-10-02 | 2023-04-13 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for a costimulatory TNF receptor |
US20180282410A1 (en) | 2015-10-02 | 2018-10-04 | Hoffmann-La Roche Inc. | Anti-cd3xrob04 bispecific t cell activating antigen binding molecules |
WO2017055392A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules |
EP3356417A1 (en) | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispecific t cell activating antigen binding molecules binding mesothelin and cd3 |
CR20180162A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Moléculas biespecíficas de unión a antígeno activadoras de células t |
RU2729371C1 (ru) | 2015-10-02 | 2020-08-06 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела, специфические к pd1 и tim3 |
US20170096495A1 (en) | 2015-10-02 | 2017-04-06 | Hoffmann-La Roche Inc. | Bispecific t cell activating antigen binding molecules |
EP3150636A1 (en) | 2015-10-02 | 2017-04-05 | F. Hoffmann-La Roche AG | Tetravalent multispecific antibodies |
ES2895034T3 (es) | 2015-10-02 | 2022-02-17 | Hoffmann La Roche | Anticuerpos anti-PD1 y procedimientos de uso |
WO2017055385A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Anti-cd3xgd2 bispecific t cell activating antigen binding molecules |
SG10201912150TA (en) | 2015-10-06 | 2020-02-27 | Alector Llc | Anti-trem2 antibodies and methods of use thereof |
CA2992900A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Bispecific antibodies with tetravalency for a costimulatory tnf receptor |
MA45326A (fr) | 2015-10-20 | 2018-08-29 | Genentech Inc | Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation |
EP3184547A1 (en) | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
MX2018005036A (es) | 2015-10-29 | 2018-08-01 | Hoffmann La Roche | Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes. |
JP7060502B2 (ja) | 2015-10-29 | 2022-04-26 | アレクトル エルエルシー | 抗Siglec-9抗体及びその使用方法 |
US10407510B2 (en) | 2015-10-30 | 2019-09-10 | Genentech, Inc. | Anti-factor D antibodies and conjugates |
MA43113B1 (fr) | 2015-10-30 | 2021-06-30 | Hoffmann La Roche | Anticorps anti-htr a1 et méthodes d'utilisation de ceux-ci |
EP3368579B1 (en) | 2015-10-30 | 2021-11-24 | F. Hoffmann-La Roche AG | Hinge modified antibody fragments and methods of making |
EP3371217A1 (en) | 2015-11-08 | 2018-09-12 | H. Hoffnabb-La Roche Ag | Methods of screening for multispecific antibodies |
RU2742606C2 (ru) | 2015-12-18 | 2021-02-09 | Чугаи Сейяку Кабусики Кайся | Антитела к с5 и способы их применения |
KR20180098625A (ko) | 2015-12-30 | 2018-09-04 | 제넨테크, 인크. | 분해가 감소된 폴리소르베이트를 갖는 제형 |
KR20180093078A (ko) | 2015-12-30 | 2018-08-20 | 제넨테크, 인크. | 단백질 제제를 위한 트립토판 유도체의 용도 |
CA3006529A1 (en) | 2016-01-08 | 2017-07-13 | F. Hoffmann-La Roche Ag | Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies |
EP3405489A1 (en) | 2016-01-20 | 2018-11-28 | Genentech, Inc. | High dose treatments for alzheimer's disease |
CA3019952A1 (en) | 2016-02-04 | 2017-08-10 | Curis, Inc. | Mutant smoothened and methods of using the same |
WO2017152102A2 (en) | 2016-03-04 | 2017-09-08 | Alector Llc | Anti-trem1 antibodies and methods of use thereof |
JP7157981B2 (ja) | 2016-03-07 | 2022-10-21 | チャールストンファーマ, エルエルシー | 抗ヌクレオリン抗体 |
WO2017159699A1 (en) | 2016-03-15 | 2017-09-21 | Chugai Seiyaku Kabushiki Kaisha | Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies |
EP3433280B1 (en) | 2016-03-22 | 2023-04-19 | F. Hoffmann-La Roche AG | Protease-activated t cell bispecific molecules |
EP3433621A1 (en) | 2016-03-25 | 2019-01-30 | H. Hoffnabb-La Roche Ag | Multiplexed total antibody and antibody-conjugated drug quantification assay |
EP3231813A1 (en) | 2016-03-29 | 2017-10-18 | F. Hoffmann-La Roche AG | Trimeric costimulatory tnf family ligand-containing antigen binding molecules |
JP6727325B2 (ja) | 2016-03-30 | 2020-07-22 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 改善されたソルターゼ |
WO2017180864A1 (en) | 2016-04-14 | 2017-10-19 | Genentech, Inc. | Anti-rspo3 antibodies and methods of use |
BR112018069890A2 (pt) | 2016-05-02 | 2019-02-05 | Hoffmann La Roche | polipeptídio de fusão que se liga de forma específica a um alvo, polipeptídio de fusão dimérico, ácido nucleico isolado, par de ácidos nucleicos isolados, célula hospedeira, método para produzir um polipeptídio de fusão, imunoconjugado, formulação farmacêutica, polipeptídio de fusão e uso do polipeptídio de fusão |
WO2017194442A1 (en) | 2016-05-11 | 2017-11-16 | F. Hoffmann-La Roche Ag | Antigen binding molecules comprising a tnf family ligand trimer and a tenascin binding moiety |
EP3243836A1 (en) | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
CN109071640B (zh) | 2016-05-11 | 2022-10-18 | 豪夫迈·罗氏有限公司 | 经修饰抗生腱蛋白抗体及使用方法 |
EP3243832A1 (en) | 2016-05-13 | 2017-11-15 | F. Hoffmann-La Roche AG | Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety |
ES2858151T3 (es) | 2016-05-20 | 2021-09-29 | Hoffmann La Roche | Conjugados de PROTAC-anticuerpo y procedimientos de uso |
CN109313200B (zh) | 2016-05-27 | 2022-10-04 | 豪夫迈·罗氏有限公司 | 用于表征位点特异性抗体-药物缀合物的生物分析性方法 |
EP3464280B1 (en) | 2016-06-06 | 2021-10-06 | F. Hoffmann-La Roche AG | Silvestrol antibody-drug conjugates and methods of use |
CA3025995C (en) | 2016-06-06 | 2023-08-08 | F. Hoffmann-La Roche Ag | Fusion proteins for ophthalmology with increased eye retention |
JP7133477B2 (ja) | 2016-06-24 | 2022-09-08 | ジェネンテック, インコーポレイテッド | 抗ポリユビキチン多重特異性抗体 |
CN109415435B (zh) | 2016-07-04 | 2024-01-16 | 豪夫迈·罗氏有限公司 | 新型抗体形式 |
CN109415444B (zh) | 2016-07-29 | 2024-03-01 | 中外制药株式会社 | 显示增加的备选fviii辅因子功能活性的双特异性抗体 |
CN109689099B (zh) | 2016-08-05 | 2023-02-28 | 中外制药株式会社 | 用于预防或治疗il-8相关疾病的组合物 |
CN109476748B (zh) | 2016-08-08 | 2023-05-23 | 豪夫迈·罗氏有限公司 | 用于癌症的治疗和诊断方法 |
WO2018047154A1 (en) | 2016-09-07 | 2018-03-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Anti-nkp46 antibodies and therapeutic use of same |
SG10201607778XA (en) | 2016-09-16 | 2018-04-27 | Chugai Pharmaceutical Co Ltd | Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use |
EP3515932B1 (en) | 2016-09-19 | 2023-11-22 | F. Hoffmann-La Roche AG | Complement factor based affinity chromatography |
UA124269C2 (uk) | 2016-09-23 | 2021-08-18 | Дженентек, Інк. | Застосування антагоністу il-13 для лікування атопічного дерматиту |
PL3519437T3 (pl) | 2016-09-30 | 2022-01-17 | F. Hoffmann-La Roche Ag | Przeciwciała dwuswoiste przeciwko p95HER2 |
JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
CN110267678A (zh) | 2016-10-29 | 2019-09-20 | 霍夫曼-拉罗奇有限公司 | 抗mic抗体和使用方法 |
TW201829463A (zh) | 2016-11-18 | 2018-08-16 | 瑞士商赫孚孟拉羅股份公司 | 抗hla-g抗體及其用途 |
CN110023334B (zh) | 2016-11-21 | 2023-11-14 | 科雅博有限责任公司 | 抗gp73抗体和免疫偶联物 |
EP3551655A2 (en) | 2016-12-07 | 2019-10-16 | Genentech, Inc. | Anti-tau antibodies and methods of their use |
WO2018106781A1 (en) | 2016-12-07 | 2018-06-14 | Genentech, Inc | Anti-tau antibodies and methods of use |
WO2018114754A1 (en) | 2016-12-19 | 2018-06-28 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
ES2847973T3 (es) | 2016-12-20 | 2021-08-04 | Hoffmann La Roche | Politerapia de anticuerpos biespecíficos anti-CD20/anti-CD3 y agonistas de 4-1BB (CD137) |
JP6850351B2 (ja) | 2016-12-21 | 2021-03-31 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 抗体のインビトロ糖鎖工学 |
EP3559250A1 (en) | 2016-12-21 | 2019-10-30 | H. Hoffnabb-La Roche Ag | Re-use of enzymes in in vitro glycoengineering of antibodies |
KR102293106B1 (ko) | 2016-12-21 | 2021-08-24 | 에프. 호프만-라 로슈 아게 | 항체의 시험관 내 당조작 방법 |
MA47200A (fr) | 2017-01-03 | 2019-11-13 | Hoffmann La Roche | Molécules bispécifiques de liaison à l'antigène comprenant un clone 20h4.9 anti-4-1bb |
WO2018136553A1 (en) | 2017-01-18 | 2018-07-26 | Genentech, Inc. | Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof |
US10738131B2 (en) | 2017-02-10 | 2020-08-11 | Genentech, Inc. | Anti-tryptase antibodies, compositions thereof, and uses thereof |
RU2750721C2 (ru) | 2017-03-10 | 2021-07-01 | Ф. Хоффманн-Ля Рош Аг | Способ получения мультиспецифических антител |
WO2018175788A1 (en) | 2017-03-22 | 2018-09-27 | Genentech, Inc. | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
AR111249A1 (es) | 2017-03-22 | 2019-06-19 | Genentech Inc | Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares |
KR20190133162A (ko) | 2017-03-28 | 2019-12-02 | 제넨테크, 인크. | 신경퇴행성 질병의 치료 방법 |
WO2018178074A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules specific for a costimulatory tnf receptor |
JP7205995B2 (ja) | 2017-03-29 | 2023-01-17 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激性tnf受容体に対する二重特異性抗原結合分子 |
WO2018178055A1 (en) | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Bispecific antigen binding molecule for a costimulatory tnf receptor |
BR112019018767A2 (pt) | 2017-04-03 | 2020-05-05 | Hoffmann La Roche | anticorpos, molécula de ligação ao antígeno biespecífica, um ou mais polinucleotídeos isolados, um ou mais vetores, célula hospedeira, método para produzir um anticorpo, composição farmacêutica, usos, método para tratar uma doença em um indivíduo e invenção |
ES2928718T3 (es) | 2017-04-03 | 2022-11-22 | Hoffmann La Roche | Inmunoconjugados de un anticuerpo anti-PD-1 con una IL-2 mutante o con IL-15 |
WO2018184965A1 (en) | 2017-04-03 | 2018-10-11 | F. Hoffmann-La Roche Ag | Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody |
TWI704158B (zh) | 2017-04-04 | 2020-09-11 | 瑞士商赫孚孟拉羅股份公司 | 能夠特異性結合至cd40及fap之新穎雙特異性抗原結合分子 |
EP4112644A1 (en) | 2017-04-05 | 2023-01-04 | F. Hoffmann-La Roche AG | Anti-lag3 antibodies |
KR102346336B1 (ko) | 2017-04-05 | 2022-01-04 | 에프. 호프만-라 로슈 아게 | Pd1 및 lag3에 특이적으로 결합하는 이중특이적 항체 |
MX2019012793A (es) | 2017-04-27 | 2020-02-13 | Tesaro Inc | Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos. |
EP3625251A1 (en) | 2017-05-15 | 2020-03-25 | University Of Rochester | Broadly neutralizing anti-influenza monoclonal antibody and uses thereof |
US11359014B2 (en) | 2017-05-16 | 2022-06-14 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
JP7299160B2 (ja) | 2017-08-03 | 2023-06-27 | アレクトル エルエルシー | 抗cd33抗体及びその使用方法 |
TWI811229B (zh) | 2017-08-03 | 2023-08-11 | 美商阿列克特有限責任公司 | 抗trem2抗體及其使用方法 |
MX2020000903A (es) | 2017-08-11 | 2020-07-22 | Genentech Inc | Anticuerpos anti-cd8 y usos de los mismos. |
IL253984A0 (en) | 2017-08-14 | 2017-09-28 | Yeda Res & Dev | Immunotherapy against aranviruses that bind through transferrin receptor 1 (tfr1 |
SG11202001551YA (en) | 2017-08-21 | 2020-03-30 | Adagene Inc | Dynamic human heavy chain antibody libraries |
KR20200054209A (ko) | 2017-08-21 | 2020-05-19 | 아다진 인크. | 동적 인간 항체 경쇄 라이브러리 |
WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | ANTI-CD137 MOLECULES AND THEIR USE |
EP3679068A2 (en) | 2017-09-08 | 2020-07-15 | Maverick Therapeutics, Inc. | CONDITIONALLY ACTIVATED BINDING MOIETIES CONTAINING Fc REGIONS |
BR112020004543A2 (pt) | 2017-09-08 | 2020-09-08 | Maverick Therapeutics, Inc. | proteínas de ligação ativadas condicionalmente restritas |
CR20210381A (es) | 2017-09-29 | 2021-09-09 | Chugai Pharmaceutical Co Ltd | MOLÉCULA DE UNIÓN AL ANTÍGENO MULTIESPECÍFICA QUE TIENE ACTIVIDAD DE SUSTITUCIÓN DE LA FUNCIÓN DE COFACTOR DEL FACTOR VIII DE COAGULACIÓN DE SANGRE (FVIII) Y FORMULACIÓN FARMACÉUTICA QUE CONTIENE TAL MOLÉCULA COMO INGREDIENTE (Divisional Exp. 2020-0158) |
WO2019086362A1 (en) | 2017-10-30 | 2019-05-09 | F. Hoffmann-La Roche Ag | Method for in vivo generation of multispecific antibodies from monospecific antibodies |
KR20200084006A (ko) | 2017-11-01 | 2020-07-09 | 에프. 호프만-라 로슈 아게 | 표적화된 ox40 작용제를 사용하는 병용 요법 |
CN111295392A (zh) | 2017-11-01 | 2020-06-16 | 豪夫迈·罗氏有限公司 | Compbody–多价靶结合物 |
JP2021500902A (ja) | 2017-11-01 | 2021-01-14 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 新規tnfファミリーリガンド三量体含有抗原結合分子 |
KR102559706B1 (ko) | 2017-11-01 | 2023-07-25 | 에프. 호프만-라 로슈 아게 | Trifab-콘톨스바디 |
WO2019086500A2 (en) | 2017-11-01 | 2019-05-09 | F. Hoffmann-La Roche Ag | Bispecific 2+1 contorsbodies |
MX2020005562A (es) | 2017-11-30 | 2020-08-20 | Genentech Inc | Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1. |
SG11202005632SA (en) | 2017-12-21 | 2020-07-29 | Hoffmann La Roche | Antibodies binding to hla-a2/wt1 |
EP3502140A1 (en) | 2017-12-21 | 2019-06-26 | F. Hoffmann-La Roche AG | Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules |
WO2019133512A1 (en) | 2017-12-29 | 2019-07-04 | Alector Llc | Anti-tmem106b antibodies and methods of use thereof |
CN111511400A (zh) | 2017-12-29 | 2020-08-07 | 豪夫迈·罗氏有限公司 | 抗vegf抗体及其使用方法 |
KR20200106525A (ko) | 2018-01-05 | 2020-09-14 | 에이씨 이뮨 에스.에이. | 미스폴딩된 tdp-43 결합 분자 |
WO2019143636A1 (en) | 2018-01-16 | 2019-07-25 | Lakepharma, Inc. | Bispecific antibody that binds cd3 and another target |
MA51676A (fr) | 2018-01-26 | 2021-05-05 | Hoffmann La Roche | Protéines de fusion il-22 fc et procédés d'utilisation |
EP3743088B1 (en) | 2018-01-26 | 2022-10-12 | F. Hoffmann-La Roche AG | Il-22 fc compositions and methods of use |
JP7268038B2 (ja) | 2018-01-31 | 2023-05-02 | アレクトル エルエルシー | 抗ms4a4a抗体及びその使用方法 |
CN111601825B (zh) | 2018-02-01 | 2022-11-29 | 信达生物制药(苏州)有限公司 | 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用 |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
TWI829667B (zh) | 2018-02-09 | 2024-01-21 | 瑞士商赫孚孟拉羅股份公司 | 結合gprc5d之抗體 |
EP3752530A1 (en) | 2018-02-14 | 2020-12-23 | ABBA Therapeutics AG | Anti-human pd-l2 antibodies |
CA3091139A1 (en) | 2018-02-21 | 2019-08-29 | Genentech, Inc. | Dosing for treatment with il-22 fc fusion proteins |
CA3092108A1 (en) | 2018-02-26 | 2019-08-29 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
EP3533459A1 (en) | 2018-03-02 | 2019-09-04 | Diaccurate | Anti-pla2-gib antibodies and the uses thereof |
EP3533460A1 (en) | 2018-03-02 | 2019-09-04 | Diaccurate | Therapeutic anti-spla2-gib antibodies and the uses thereof |
US20210024632A1 (en) | 2018-03-05 | 2021-01-28 | Etablissement Francais Du Sang | Recombinant single chain immunoglobulins |
JP7159332B2 (ja) | 2018-03-13 | 2022-10-24 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 4-1bbアゴニストと抗cd20抗体の治療的組み合わせ |
WO2019175125A1 (en) | 2018-03-13 | 2019-09-19 | F. Hoffmann-La Roche Ag | Combination therapy with targeted 4-1bb (cd137) agonists |
US20200040103A1 (en) | 2018-03-14 | 2020-02-06 | Genentech, Inc. | Anti-klk5 antibodies and methods of use |
JP2021518343A (ja) | 2018-03-15 | 2021-08-02 | 中外製薬株式会社 | ジカウイルスに対して交差反応性を有する抗デングウイルス抗体および使用方法 |
EP3778639A4 (en) | 2018-04-02 | 2021-06-09 | Mab-Venture Biopharm Co., Ltd. | ANTIBODIES BINDING TO LYMPHOCYTAIR ACTIVATION GENE 3 (LAG-3) AND ITS USE |
TW202011029A (zh) | 2018-04-04 | 2020-03-16 | 美商建南德克公司 | 偵測及定量fgf21之方法 |
AR114284A1 (es) | 2018-04-13 | 2020-08-12 | Hoffmann La Roche | Moléculas de unión a antígeno dirigidas a her2 que comprenden 4-1bbl |
AR115052A1 (es) | 2018-04-18 | 2020-11-25 | Hoffmann La Roche | Anticuerpos multiespecíficos y utilización de los mismos |
AR114789A1 (es) | 2018-04-18 | 2020-10-14 | Hoffmann La Roche | Anticuerpos anti-hla-g y uso de los mismos |
FR3080621B1 (fr) | 2018-04-26 | 2022-12-09 | Univ Limoges | Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde |
WO2019213384A1 (en) | 2018-05-03 | 2019-11-07 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
MX2020011828A (es) | 2018-05-25 | 2021-02-09 | Alector Llc | Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos. |
JP7372237B2 (ja) | 2018-06-04 | 2023-10-31 | 中外製薬株式会社 | 細胞質内での半減期が変化した抗原結合分子 |
CN112512638A (zh) | 2018-06-08 | 2021-03-16 | 艾利妥 | 抗siglec-7抗体及其使用方法 |
MX2020014091A (es) | 2018-06-23 | 2021-05-27 | Genentech Inc | Metodos para tratar el cancer de pulmon con un antagonista de fijacion al eje pd-1, un agente de platino y un inhibidor de la topoisomerasa ii. |
CA3099176A1 (en) | 2018-06-29 | 2020-01-02 | Alector Llc | Anti-sirp-beta1 antibodies and methods of use thereof |
EP3818082A1 (en) | 2018-07-04 | 2021-05-12 | F. Hoffmann-La Roche AG | Novel bispecific agonistic 4-1bb antigen binding molecules |
CN111372655A (zh) | 2018-07-13 | 2020-07-03 | 艾利妥 | 抗分拣蛋白抗体及其使用方法 |
MX2021000268A (es) | 2018-07-17 | 2021-06-08 | Humabs Biomed Sa | Anticuerpos contra especies de campylobacter. |
JP7072715B2 (ja) | 2018-07-20 | 2022-05-20 | サーフィス オンコロジー インコーポレイテッド | 抗cd112r組成物及び方法 |
WO2020023920A1 (en) | 2018-07-27 | 2020-01-30 | Alector Llc | Anti-siglec-5 antibodies and methods of use thereof |
AU2019315226A1 (en) | 2018-08-03 | 2021-03-18 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule containing two antigen-binding domains that are linked to each other |
JP2021533149A (ja) | 2018-08-08 | 2021-12-02 | ジェネンテック, インコーポレイテッド | タンパク質製剤のためのトリプトファン誘導体及びl−メチオニンの使用 |
AU2019318031A1 (en) | 2018-08-10 | 2021-02-25 | Chugai Seiyaku Kabushiki Kaisha | Anti-CD137 antigen-binding molecule and utilization thereof |
TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商23與我有限公司 | 抗il1rap抗體及其使用方法 |
TW202016307A (zh) | 2018-08-31 | 2020-05-01 | 美商阿列克特有限責任公司 | 抗cd33 抗體及其使用方法 |
GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
EP4249917A3 (en) | 2018-09-21 | 2023-11-08 | F. Hoffmann-La Roche AG | Diagnostic methods for triple-negative breast cancer |
CN112654641A (zh) | 2018-10-01 | 2021-04-13 | 豪夫迈·罗氏有限公司 | 具有与cd40的三价结合的双特异性抗原结合分子 |
UA126188C2 (uk) | 2018-10-01 | 2022-08-25 | Ф. Хоффманн-Ля Рош Аг | Біспецифічна антигензв'язувальна молекула, яка містить домен зв'язування з fap та домен зв'язування з сd40 |
WO2020081493A1 (en) | 2018-10-16 | 2020-04-23 | Molecular Templates, Inc. | Pd-l1 binding proteins |
TW202037381A (zh) | 2018-10-24 | 2020-10-16 | 瑞士商赫孚孟拉羅股份公司 | 綴合化學降解誘導劑及使用方法 |
AU2018451747A1 (en) | 2018-12-06 | 2021-06-17 | F. Hoffmann-La Roche Ag | Combination therapy of diffuse large B-cell lymphoma comprising an anti-CD79b immunoconjugates, an alkylating agent and an anti-CD20 antibody |
WO2020123275A1 (en) | 2018-12-10 | 2020-06-18 | Genentech, Inc. | Photocrosslinking peptides for site specific conjugation to fc-containing proteins |
EP4292659A3 (en) | 2018-12-19 | 2024-03-20 | Humabs Biomed SA | Antibodies that neutralize hepatitis b virus and uses thereof |
TW202035442A (zh) | 2018-12-20 | 2020-10-01 | 美商建南德克公司 | 經修飾之抗體Fc及其使用方法 |
AR117327A1 (es) | 2018-12-20 | 2021-07-28 | 23Andme Inc | Anticuerpos anti-cd96 y métodos de uso de estos |
AU2019410075B2 (en) | 2018-12-21 | 2022-08-25 | F. Hoffmann-La Roche Ag | Antibodies binding to CD3 |
AR117728A1 (es) | 2018-12-21 | 2021-08-25 | Hoffmann La Roche | Moléculas superagonistas de unión al antígeno cd28 con diana tumoral |
SG11202106100VA (en) | 2018-12-21 | 2021-07-29 | 23Andme Inc | Anti-il-36 antibodies and methods of use thereof |
CR20210326A (es) | 2018-12-21 | 2021-09-10 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor |
JP2022515543A (ja) | 2018-12-30 | 2022-02-18 | エフ.ホフマン-ラ ロシュ アーゲー | 抗ウサギcd19抗体および使用方法 |
SG11202107981VA (en) | 2019-01-22 | 2021-08-30 | Genentech Inc | Immunoglobulin a antibodies and methods of production and use |
GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
JP2022521773A (ja) | 2019-02-27 | 2022-04-12 | ジェネンテック, インコーポレイテッド | 抗tigit抗体と抗cd20抗体又は抗cd38抗体とによる処置のための投薬 |
JP2022524337A (ja) | 2019-03-05 | 2022-05-02 | 武田薬品工業株式会社 | 腫瘍抗原を標的とするfc領域及び部分を含有する条件的に活性化された結合タンパク質 |
EP3934762A1 (en) | 2019-03-05 | 2022-01-12 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
KR20210138588A (ko) | 2019-03-08 | 2021-11-19 | 제넨테크, 인크. | 세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법 |
EP3943108A4 (en) | 2019-03-19 | 2023-01-04 | Chugai Seiyaku Kabushiki Kaisha | ANTIGEN-BINDING MOLECULE CONTAINING AN ANTIGEN-BINDING DOMAIN WHOSE ANTIGEN-BINDING ACTIVITY IS ALTERED DEPENDING ON THE MTA, AND BANK FOR OBTAINING SUCH ANTIGEN-BINDING DOMAIN |
EP3952996A1 (en) | 2019-04-12 | 2022-02-16 | F. Hoffmann-La Roche AG | Bispecific antigen binding molecules comprising lipocalin muteins |
JP2022529154A (ja) | 2019-04-19 | 2022-06-17 | ジェネンテック, インコーポレイテッド | 抗mertk抗体及びその使用方法 |
AU2020261250A1 (en) | 2019-04-25 | 2021-10-14 | F. Hoffmann-La Roche Ag | Generation of antibody-derived polypeptides by polypeptide chain exchange |
MX2021012872A (es) | 2019-04-25 | 2021-11-17 | Hoffmann La Roche | Polipeptidos multiespecificos terapeuticos activados mediante intercambio de cadenas polipeptidicas. |
CN113767114A (zh) | 2019-04-25 | 2021-12-07 | 豪夫迈·罗氏有限公司 | 半衰期延长的可活化治疗性多特异性多肽 |
BR112021022815A2 (pt) | 2019-05-14 | 2021-12-28 | Genentech Inc | Métodos para tratar linfoma folicular, kits, imunoconjugados e polatuzumabe vedotina |
SG11202112453TA (en) | 2019-05-23 | 2021-12-30 | Ac Immune Sa | Anti-tdp-43 binding molecules and uses thereof |
TW202112817A (zh) | 2019-06-11 | 2021-04-01 | 美商阿列克特有限責任公司 | 抗揀選蛋白抗體之使用方法 |
CN114127123A (zh) | 2019-06-26 | 2022-03-01 | 豪夫迈·罗氏有限公司 | 结合cea的抗体与4-1bbl的融合 |
CN114531878A (zh) | 2019-06-27 | 2022-05-24 | 豪夫迈·罗氏有限公司 | 新颖icos抗体及包含它们的肿瘤靶向抗原结合分子 |
JP2022538178A (ja) | 2019-06-28 | 2022-08-31 | エフ.ホフマン-ラ ロシュ アーゲー | 抗体の製造方法 |
TW202115115A (zh) | 2019-07-02 | 2021-04-16 | 瑞士商赫孚孟拉羅股份公司 | 免疫結合物 |
CR20220049A (es) | 2019-07-10 | 2022-03-02 | Chugai Pharmaceutical Co Ltd | Moléculas de unión a claudina-6 y usos de las mismas |
AR119382A1 (es) | 2019-07-12 | 2021-12-15 | Hoffmann La Roche | Anticuerpos de pre-direccionamiento y métodos de uso |
AR119393A1 (es) | 2019-07-15 | 2021-12-15 | Hoffmann La Roche | Anticuerpos que se unen a nkg2d |
CN114174338A (zh) | 2019-07-31 | 2022-03-11 | 豪夫迈·罗氏有限公司 | 与gprc5d结合的抗体 |
EP4003519A2 (en) | 2019-07-31 | 2022-06-01 | Alector LLC | Anti-ms4a4a antibodies and methods of use thereof |
CA3144524A1 (en) | 2019-07-31 | 2021-02-04 | F. Hoffmann-La Roche Ag | Antibodies binding to gprc5d |
AU2020325770B2 (en) | 2019-08-06 | 2022-08-25 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
JP2022544785A (ja) | 2019-08-13 | 2022-10-21 | エルピス・バイオファーマシューティカルズ | 改変インターロイキン2受容体ベータアゴニスト |
EP3786180A1 (en) | 2019-08-27 | 2021-03-03 | Diaccurate | Antibodies and the uses thereof |
BR112022003698A2 (pt) | 2019-08-29 | 2022-05-24 | Vir Biotechnology Inc | Método de tratamento de uma infecção pelo vírus da hepatite b e composição farmacêutica |
EP4021502A1 (en) | 2019-08-29 | 2022-07-06 | VIR Biotechnology, Inc. | Compositions and methods for treatment of influenza a infection |
JP2022547483A (ja) | 2019-09-04 | 2022-11-14 | ジェネンテック, インコーポレイテッド | Cd8結合性作用剤およびその使用 |
AU2020345913A1 (en) | 2019-09-12 | 2022-02-24 | Genentech, Inc. | Compositions and methods of treating lupus nephritis |
CR20220156A (es) | 2019-09-18 | 2022-05-23 | Genentech Inc | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso |
WO2021055816A1 (en) | 2019-09-18 | 2021-03-25 | Molecular Templates, Inc. | Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds |
EP4036116A4 (en) | 2019-09-27 | 2024-01-24 | Nanjing Genscript Biotech Co Ltd | ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF |
CA3151406A1 (en) | 2019-09-27 | 2021-04-01 | Raymond D. Meng | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
EP4034160A1 (en) | 2019-09-27 | 2022-08-03 | Janssen Biotech, Inc. | Anti-ceacam antibodies and uses thereof |
BR112022007216A2 (pt) | 2019-10-18 | 2022-08-23 | Genentech Inc | Métodos para tratamento de linfoma difuso, kit e imunoconjugado |
JP2022554187A (ja) | 2019-10-24 | 2022-12-28 | ミノトール セラピューティクス インコーポレイテッド | キメラサイトカイン改変抗体およびその使用方法 |
CA3155922A1 (en) | 2019-11-06 | 2021-05-14 | Huang Huang | Diagnostic and therapeutic methods for treatment of hematologic cancers |
CN114641270A (zh) | 2019-11-15 | 2022-06-17 | 豪夫迈·罗氏有限公司 | 防止水性蛋白质溶液中可见颗粒的形成 |
KR20220127243A (ko) | 2019-12-12 | 2022-09-19 | 알렉터 엘엘씨 | 항-cd33 항체의 사용 방법 |
US11897968B2 (en) | 2019-12-13 | 2024-02-13 | Alector Llc | Anti-MerTK antibodies and methods of use thereof |
WO2021119505A1 (en) | 2019-12-13 | 2021-06-17 | Genentech, Inc. | Anti-ly6g6d antibodies and methods of use |
WO2021122875A1 (en) | 2019-12-18 | 2021-06-24 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a2/mage-a4 |
IL293310A (en) | 2019-12-18 | 2022-07-01 | Hoffmann La Roche | Bispecific anti-ccl2 antibodies |
KR20220118527A (ko) | 2019-12-23 | 2022-08-25 | 제넨테크, 인크. | 아포지질단백질 l1-특이적 항체 및 이용 방법 |
BR112022011723A2 (pt) | 2019-12-27 | 2022-09-06 | Chugai Pharmaceutical Co Ltd | Anticorpo anti-ctla-4 e uso do mesmo |
CA3162009A1 (en) | 2020-01-09 | 2021-07-15 | F. Hoffmann-La Roche Ag | New 4-1bbl trimer-containing antigen binding molecules |
CN110818795B (zh) | 2020-01-10 | 2020-04-24 | 上海复宏汉霖生物技术股份有限公司 | 抗tigit抗体和使用方法 |
EP4090673A1 (en) | 2020-01-15 | 2022-11-23 | Trutino Biosciences Inc. | Cytokine il-2 prodrugs comprising a cleavable linker |
WO2022050954A1 (en) | 2020-09-04 | 2022-03-10 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
WO2021194481A1 (en) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies |
CN115768800A (zh) | 2020-01-31 | 2023-03-07 | 克利夫兰诊所基金会 | 抗苗勒管激素受体2抗体和使用方法 |
WO2021158521A1 (en) | 2020-02-03 | 2021-08-12 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
EP4105238A4 (en) | 2020-02-10 | 2024-03-27 | Shanghai Escugen Biotechnology Co Ltd | CLAUDIN 18.2 ANTIBODIES AND THEIR USE |
KR20220139357A (ko) | 2020-02-10 | 2022-10-14 | 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 | Cldn18.2 항체 및 그의 사용 |
TW202144395A (zh) | 2020-02-12 | 2021-12-01 | 日商中外製藥股份有限公司 | 用於癌症之治療的抗cd137抗原結合分子 |
BR112022017048A2 (pt) | 2020-02-26 | 2022-11-16 | Vir Biotechnology Inc | Anticorpos contra sars-cov-2 e métodos para usar os mesmos |
WO2021183849A1 (en) | 2020-03-13 | 2021-09-16 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
CN115279408A (zh) | 2020-03-19 | 2022-11-01 | 基因泰克公司 | 同种型选择性抗TGF-β抗体及使用方法 |
AU2021242249A1 (en) | 2020-03-24 | 2022-08-18 | Genentech, Inc. | Tie2-binding agents and methods of use |
JP2023519962A (ja) | 2020-03-31 | 2023-05-15 | アレクトル エルエルシー | 抗mertk抗体及びその使用方法 |
IL296802A (en) | 2020-03-31 | 2022-11-01 | Chugai Pharmaceutical Co Ltd | A method for the production of multispecific antigen binding molecules |
AR121706A1 (es) | 2020-04-01 | 2022-06-29 | Hoffmann La Roche | Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap |
CA3170570A1 (en) | 2020-04-01 | 2021-10-07 | James J. KOBIE | Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses |
JPWO2021201202A1 (zh) | 2020-04-02 | 2021-10-07 | ||
WO2021203053A1 (en) | 2020-04-03 | 2021-10-07 | Vir Biotechnology, Inc. | Immunotherapy targeting a conserved region in sars coronaviruses |
WO2021207662A1 (en) | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
WO2021211775A1 (en) | 2020-04-14 | 2021-10-21 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 and methods of using the same |
KR20230004494A (ko) | 2020-04-15 | 2023-01-06 | 에프. 호프만-라 로슈 아게 | 면역접합체 |
CA3175530A1 (en) | 2020-04-24 | 2021-10-28 | Genentech, Inc. | Methods of using anti-cd79b immunoconjugates |
KR20230002261A (ko) | 2020-04-28 | 2023-01-05 | 더 락커펠러 유니버시티 | 항-sars-cov-2 중화 항체 및 이의 사용 방법 |
CA3174692A1 (en) | 2020-04-30 | 2021-11-04 | Genentech, Inc. | Kras specific antibodies and uses thereof |
CN116963782A (zh) | 2020-05-03 | 2023-10-27 | 联宁(苏州)生物制药有限公司 | 包含抗trop-2抗体的抗体药物偶联物 |
CA3177169A1 (en) | 2020-05-08 | 2021-11-11 | Vir Biotechnology, Inc. | Antibodies against sars-cov-2 |
WO2021231278A1 (en) | 2020-05-11 | 2021-11-18 | F. Hoffmann-La Roche Ag | Combination therapy with modified pbmcs and an immunoconjugate |
JP2023520249A (ja) | 2020-05-15 | 2023-05-16 | エフ. ホフマン-ラ ロシュ アーゲー | 非経口タンパク質溶液中の可視粒子形成の防止方法 |
CN115605185A (zh) | 2020-05-19 | 2023-01-13 | 豪夫迈·罗氏有限公司(Ch) | 螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途 |
BR112022024339A2 (pt) | 2020-05-29 | 2022-12-27 | 23Andme Inc | Anticorpos anti cd200r1 e métodos de uso dos mesmos |
WO2021247925A1 (en) | 2020-06-03 | 2021-12-09 | Vir Biotechnology, Inc. | Structure-guided immunotherapy against sars-cov-2 |
MX2022015206A (es) | 2020-06-08 | 2023-01-05 | Hoffmann La Roche | Anticuerpos anti-hbv y metodos de uso. |
CA3180477A1 (en) | 2020-06-12 | 2021-12-16 | Elizabeth Alexander | Antibody therapies for sars-cov-2 infection |
WO2021257503A1 (en) | 2020-06-16 | 2021-12-23 | Genentech, Inc. | Methods and compositions for treating triple-negative breast cancer |
US20210395366A1 (en) | 2020-06-18 | 2021-12-23 | Genentech, Inc. | Treatment with anti-tigit antibodies and pd-1 axis binding antagonists |
WO2021255146A1 (en) | 2020-06-19 | 2021-12-23 | F. Hoffmann-La Roche Ag | Antibodies binding to cd3 and cea |
TW202216767A (zh) | 2020-06-19 | 2022-05-01 | 瑞士商赫孚孟拉羅股份公司 | 與CD3及FolR1結合之抗體 |
AR122658A1 (es) | 2020-06-19 | 2022-09-28 | Hoffmann La Roche | Anticuerpos que se unen a cd3 |
JP2023529981A (ja) | 2020-06-19 | 2023-07-12 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | 免疫活性化Fcドメイン結合分子 |
IL298402A (en) | 2020-06-19 | 2023-01-01 | Hoffmann La Roche | Antibodies that bind to CD3 and CD19 |
CR20220604A (es) | 2020-06-19 | 2023-01-23 | Hoffmann La Roche | Anticuerpos biespecíficos para linfocitos t activados por proteasa |
JP2023531222A (ja) | 2020-06-22 | 2023-07-21 | アルミラル・ソシエダッド・アノニマ | 抗il-36抗体およびその使用方法 |
KR20230016206A (ko) | 2020-06-23 | 2023-02-01 | 에프. 호프만-라 로슈 아게 | Her2를 표적으로 하는 작용성 CD28 항원 결합 분자 |
US20230242621A1 (en) | 2020-06-24 | 2023-08-03 | Vir Biotechnology, Inc. | Engineered hepatitis b virus neutralizing antibodies and uses thereof |
EP4172203A1 (en) | 2020-06-25 | 2023-05-03 | F. Hoffmann-La Roche AG | Anti-cd3/anti-cd28 bispecific antigen binding molecules |
JP2023532764A (ja) | 2020-07-07 | 2023-07-31 | エフ. ホフマン-ラ ロシュ アーゲー | 治療用タンパク質製剤の安定剤としての代替界面活性剤 |
KR20230037578A (ko) | 2020-07-10 | 2023-03-16 | 에프. 호프만-라 로슈 아게 | 암 세포에 결합하고 방사성 핵종을 상기 세포로 표적화하는 항체 |
WO2022016037A1 (en) | 2020-07-17 | 2022-01-20 | Genentech, Inc. | Anti-notch2 antibodies and methods of use |
JP2023535409A (ja) | 2020-07-21 | 2023-08-17 | ジェネンテック, インコーポレイテッド | Brm分解の抗体コンジュゲート化化学的誘導物質及びbrm分解の方法 |
GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
AU2021316017A1 (en) | 2020-07-31 | 2023-02-16 | F. Hoffmann-La Roche Ag | Anti-integrin beta7 antibody formulations and devices |
BR112023002123A2 (pt) | 2020-08-07 | 2023-03-07 | Genentech Inc | Proteína de fusão fc, ácidos nucleicos isolados, método de produção da proteína de fusão fc, formulação farmacêutica, métodos para expandir o número de células dendríticas (dcs) em um indivíduo e para tratar um câncer, proteína fc sem efetora e anticorpo |
IL276627A (en) | 2020-08-10 | 2022-03-01 | Yeda Res & Dev | Compositions for diagnosis and treatment of coronavirus infections |
EP4196162A1 (en) | 2020-08-14 | 2023-06-21 | AC Immune SA | Humanized anti-tdp-43 binding molecules and uses thereof |
EP4204448A2 (en) | 2020-08-27 | 2023-07-05 | cureab GmbH | Anti-golph2 antibodies for macrophage and dendritic cell differentiation |
US20230416371A1 (en) | 2020-08-28 | 2023-12-28 | Chugai Seiyaku Kabushiki Kaisha | Heterodimer fc polypeptide |
TW202227496A (zh) | 2020-09-14 | 2022-07-16 | 瑞士商伊克諾斯科學公司 | 結合至il1rap之抗體及其用途 |
IL301503A (en) | 2020-09-23 | 2023-05-01 | Yeda res & development co ltd | Methods and preparations for the treatment of the disease caused by the corona virus |
WO2022066973A1 (en) | 2020-09-24 | 2022-03-31 | Fred Hutchinson Cancer Research Center | Immunotherapy targeting pbk or oip5 antigens |
JP2023542528A (ja) | 2020-09-24 | 2023-10-10 | フレッド ハッチンソン キャンサー センター | Sox2抗原を標的とする免疫療法 |
CA3194162A1 (en) | 2020-09-28 | 2022-03-31 | Humabs Biomed Sa | Antibodies against sars-cov-2 |
CA3193952A1 (en) | 2020-10-05 | 2022-04-14 | Bernard Martin Fine | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
JP2023545821A (ja) | 2020-10-16 | 2023-10-31 | ジェネンテック, インコーポレイテッド | 抗iCaspase切断基質抗体および使用方法 |
AU2021366287A1 (en) | 2020-10-20 | 2023-04-13 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments specifically binding to Gremlin-1 and uses thereof |
WO2022084210A1 (en) | 2020-10-20 | 2022-04-28 | F. Hoffmann-La Roche Ag | Combination therapy of pd-1 axis binding antagonists and lrrk2 inhitibors |
WO2022086957A1 (en) | 2020-10-20 | 2022-04-28 | Genentech, Inc. | Peg-conjugated anti-mertk antibodies and methods of use |
CA3196539A1 (en) | 2020-11-04 | 2022-05-12 | Chi-Chung Li | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies |
US20220153842A1 (en) | 2020-11-04 | 2022-05-19 | Genentech, Inc. | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates |
JP2023548069A (ja) | 2020-11-04 | 2023-11-15 | ジェネンテック, インコーポレイテッド | 抗cd20/抗cd3二重特異性抗体の皮下投薬 |
EP4240758A1 (en) | 2020-11-04 | 2023-09-13 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
JP2023549316A (ja) | 2020-11-16 | 2023-11-24 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Fapを標的としたcd40アゴニストとの併用療法 |
EP4247844A1 (en) | 2020-11-23 | 2023-09-27 | VIR Biotechnology, Inc. | Antibodies against influenza a viruses |
TW202229329A (zh) | 2020-11-23 | 2022-08-01 | 美商維爾生物科技股份有限公司 | 針對流感神經胺酸酶的廣泛中和抗體 |
JP2023551667A (ja) | 2020-11-23 | 2023-12-12 | ヴィア・バイオテクノロジー・インコーポレイテッド | 抗-インフルエンザ抗体及びその組合せ |
WO2022115486A1 (en) | 2020-11-25 | 2022-06-02 | Vir Biotechnology, Inc. | Antibodies that bind to multiple betacoronaviruses |
WO2022120352A1 (en) | 2020-12-02 | 2022-06-09 | Alector Llc | Methods of use of anti-sortilin antibodies |
PE20232045A1 (es) | 2020-12-04 | 2023-12-27 | Hoffmann La Roche | Polipeptidos de interleucina-2 mutante dependientes del ph |
US20230340083A1 (en) | 2020-12-08 | 2023-10-26 | Vir Biotechnology, Inc. | Antibodies and methods for treatment of influenza a infection |
WO2022129120A1 (en) | 2020-12-17 | 2022-06-23 | F. Hoffmann-La Roche Ag | Anti-hla-g antibodies and use thereof |
CA3207090A1 (en) | 2021-01-06 | 2022-07-14 | F. Hoffmann-La Roche Ag | Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody |
WO2022148853A1 (en) | 2021-01-11 | 2022-07-14 | F. Hoffmann-La Roche Ag | Immunoconjugates |
EP4277705A1 (en) | 2021-01-12 | 2023-11-22 | F. Hoffmann-La Roche AG | Split antibodies which bind to cancer cells and target radionuclides to said cells |
US20220227844A1 (en) | 2021-01-15 | 2022-07-21 | The Rockefeller University | Neutralizing anti-sars-cov-2 antibodies |
WO2022159842A1 (en) | 2021-01-25 | 2022-07-28 | Vir Biotechnology, Inc. | Antibody combination therapies for sars-cov-2 infection |
TW202245838A (zh) | 2021-01-26 | 2022-12-01 | 美商維爾生物科技股份有限公司 | 用於治療b型肝炎病毒感染的組成物及方法 |
WO2022162587A1 (en) | 2021-01-27 | 2022-08-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
WO2022162203A1 (en) | 2021-01-28 | 2022-08-04 | Vaccinvent Gmbh | Method and means for modulating b-cell mediated immune responses |
CA3206395A1 (en) | 2021-01-28 | 2022-08-04 | Hassan JUMAA-WEINACHT | Method and means for modulating b-cell mediated immune responses |
CN117120084A (zh) | 2021-01-28 | 2023-11-24 | 维肯芬特有限责任公司 | 用于调节b细胞介导的免疫应答的方法和手段 |
WO2022169872A1 (en) | 2021-02-03 | 2022-08-11 | Genentech, Inc. | Multispecific binding protein degrader platform and methods of use |
US20240034796A1 (en) | 2021-02-04 | 2024-02-01 | Genuv Inc. | Anti-pd-1 antibody and use thereof |
JP2024506321A (ja) | 2021-02-09 | 2024-02-13 | ヒューマブス・バイオメッド・ソシエテ・アノニム | 呼吸器合胞体ウイルスおよび他のパラミクソウイルスに対する抗体およびその使用方法 |
CA3210069A1 (en) | 2021-03-03 | 2022-09-09 | Tong Zhu | Antibody-drug conjugates comprising an anti-bcma antibody |
AR125074A1 (es) | 2021-03-12 | 2023-06-07 | Genentech Inc | Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5 / klk7 y métodos de uso |
JP2024511970A (ja) | 2021-03-15 | 2024-03-18 | ジェネンテック, インコーポレイテッド | ループス腎炎の治療の組成物及び方法 |
EP4308242A1 (en) | 2021-03-17 | 2024-01-24 | Molecular Templates, Inc. | Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens |
JP2024512002A (ja) | 2021-03-18 | 2024-03-18 | アレクトル エルエルシー | 抗tmem106b抗体、及び、その使用方法 |
WO2022197877A1 (en) | 2021-03-19 | 2022-09-22 | Genentech, Inc. | Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents |
WO2022204202A1 (en) | 2021-03-23 | 2022-09-29 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
JP2024511610A (ja) | 2021-03-23 | 2024-03-14 | アレクトル エルエルシー | コロナウイルス感染の治療及び予防のための抗tmem106b抗体 |
EP4067376A1 (en) | 2021-03-30 | 2022-10-05 | Diaccurate | Anti-pla2g1b monoclonal antibodies and uses thereof |
JP2024512709A (ja) | 2021-03-30 | 2024-03-19 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | プロテアーゼ活性化ポリペプチド |
WO2022206872A1 (zh) | 2021-03-31 | 2022-10-06 | 江苏恒瑞医药股份有限公司 | 截短的taci多肽及其融合蛋白和用途 |
AR125344A1 (es) | 2021-04-15 | 2023-07-05 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-c1s |
CA3217865A1 (en) | 2021-04-28 | 2022-11-03 | Minotaur Therapeutics, Inc. | Humanized chimeric bovine antibodies and methods of use |
KR20240005691A (ko) | 2021-04-30 | 2024-01-12 | 에프. 호프만-라 로슈 아게 | 항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약 |
EP4334343A2 (en) | 2021-05-06 | 2024-03-13 | The Rockefeller University | Neutralizing anti-sars- cov-2 antibodies and methods of use thereof |
CN117396232A (zh) | 2021-05-12 | 2024-01-12 | 基因泰克公司 | 使用抗cd79b免疫缀合物治疗弥漫性大b细胞淋巴瘤的方法 |
EP4339207A1 (en) | 2021-05-12 | 2024-03-20 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen binding molecule specifically binding to rankl and ngf, and medical use thereof |
EP4337317A1 (en) | 2021-05-14 | 2024-03-20 | Genentech, Inc. | Agonists of trem2 |
AU2022273737A1 (en) | 2021-05-14 | 2023-11-16 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen-binding molecule |
WO2022243261A1 (en) | 2021-05-19 | 2022-11-24 | F. Hoffmann-La Roche Ag | Agonistic cd40 antigen binding molecules targeting cea |
AU2022280767A1 (en) | 2021-05-24 | 2024-01-18 | Humabs Biomed Sa | Engineered polypeptides |
AR126009A1 (es) | 2021-06-02 | 2023-08-30 | Hoffmann La Roche | Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam |
US20230036592A1 (en) | 2021-06-03 | 2023-02-02 | Surface Oncology, Inc. | Methods of treating cancer with an anti-cd39 antibody and pembrolizumab |
JP2024520261A (ja) | 2021-06-04 | 2024-05-24 | 中外製薬株式会社 | 抗ddr2抗体およびその使用 |
AU2022289684A1 (en) | 2021-06-09 | 2023-10-05 | F. Hoffmann-La Roche Ag | Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer |
EP4355786A1 (en) | 2021-06-16 | 2024-04-24 | Alector LLC | Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof |
WO2022266221A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Monovalent anti-mertk antibodies and methods of use thereof |
WO2022266659A1 (en) | 2021-06-17 | 2022-12-22 | Genentech, Inc. | Anti-ubiquitination antibodies and methods of use |
WO2022263638A1 (en) | 2021-06-17 | 2022-12-22 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
CA3221735A1 (en) | 2021-06-18 | 2022-12-22 | F. Hoffmann-La Roche Ag | Bispecific anti-ccl2 antibodies |
WO2022270611A1 (ja) | 2021-06-25 | 2022-12-29 | 中外製薬株式会社 | 抗ctla-4抗体 |
WO2022270612A1 (ja) | 2021-06-25 | 2022-12-29 | 中外製薬株式会社 | 抗ctla-4抗体の使用 |
PE20240638A1 (es) | 2021-07-14 | 2024-03-27 | Genentech Inc | Anticuerpos anti-receptor de quimiocinas de motivo c-c 8 (ccr8) y metodos de uso |
TW202317635A (zh) | 2021-07-14 | 2023-05-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 特異性結合hgfr和egfr的抗原結合分子及其醫藥用途 |
WO2023004368A1 (en) | 2021-07-21 | 2023-01-26 | Trutino Biosciences Inc. | Linker polypeptides |
WO2023004386A1 (en) | 2021-07-22 | 2023-01-26 | Genentech, Inc. | Brain targeting compositions and methods of use thereof |
CN117730102A (zh) | 2021-07-22 | 2024-03-19 | 豪夫迈·罗氏有限公司 | 异二聚体Fc结构域抗体 |
WO2023012147A1 (en) | 2021-08-03 | 2023-02-09 | F. Hoffmann-La Roche Ag | Bispecific antibodies and methods of use |
CN117858905A (zh) | 2021-08-19 | 2024-04-09 | 豪夫迈·罗氏有限公司 | 多价抗变体fc区抗体及使用方法 |
KR20240049296A (ko) | 2021-08-27 | 2024-04-16 | 제넨테크, 인크. | 타우 병증을 치료하는 방법 |
WO2023028603A2 (en) | 2021-08-27 | 2023-03-02 | Humabs Biomed Sa | Engineered compositions |
TW202325727A (zh) | 2021-08-30 | 2023-07-01 | 美商建南德克公司 | 抗聚泛素多特異性抗體 |
CA3230613A1 (en) | 2021-09-01 | 2023-03-09 | Daren J. AUSTIN | Antibody therapies for sars-cov-2 infection in pediatric subjects |
WO2023034871A1 (en) | 2021-09-01 | 2023-03-09 | Vir Biotechnology, Inc. | High concentration antibody therapies for sars-cov-2 infection |
WO2023036815A1 (en) | 2021-09-07 | 2023-03-16 | Etablissement Francais Du Sang | Targeted regulation of platelet and megakaryocyte activation by heteroreceptor co-clustering |
WO2023039442A1 (en) | 2021-09-08 | 2023-03-16 | Vir Biotechnology, Inc. | Broadly neutralizing antibody combination therapies for sars-cov-2 infection |
CN117813323A (zh) | 2021-09-23 | 2024-04-02 | 江苏恒瑞医药股份有限公司 | 抗klb抗体及用途 |
WO2023053282A1 (ja) | 2021-09-29 | 2023-04-06 | 中外製薬株式会社 | がんの治療に用いるための細胞傷害誘導治療剤 |
WO2023056403A1 (en) | 2021-09-30 | 2023-04-06 | Genentech, Inc. | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
CN117916273A (zh) | 2021-09-30 | 2024-04-19 | 江苏恒瑞医药股份有限公司 | 抗il23抗体融合蛋白及用途 |
WO2023058705A1 (ja) | 2021-10-08 | 2023-04-13 | 中外製薬株式会社 | 抗hla-dq2.5抗体の製剤 |
WO2023062050A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | New interleukin-7 immunoconjugates |
WO2023062048A1 (en) | 2021-10-14 | 2023-04-20 | F. Hoffmann-La Roche Ag | Alternative pd1-il7v immunoconjugates for the treatment of cancer |
WO2023069919A1 (en) | 2021-10-19 | 2023-04-27 | Alector Llc | Anti-cd300lb antibodies and methods of use thereof |
AU2022379952A1 (en) | 2021-11-05 | 2024-05-16 | American Diagnostics & Therapy, Llc (Adxrx) | Monoclonal antibodies against carcinoembryonic antigens, and their uses |
WO2023081898A1 (en) | 2021-11-08 | 2023-05-11 | Alector Llc | Soluble cd33 as a biomarker for anti-cd33 efficacy |
WO2023086807A1 (en) | 2021-11-10 | 2023-05-19 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
AU2022390134A1 (en) | 2021-11-16 | 2024-05-16 | Ac Immune Sa | Novel molecules for therapy and diagnosis |
CA3236006A1 (en) | 2021-11-16 | 2023-05-25 | Genentech, Inc. | Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab |
AR127887A1 (es) | 2021-12-10 | 2024-03-06 | Hoffmann La Roche | Anticuerpos que se unen a cd3 y plap |
AR128031A1 (es) | 2021-12-20 | 2024-03-20 | Hoffmann La Roche | Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden |
WO2023141445A1 (en) | 2022-01-19 | 2023-07-27 | Genentech, Inc. | Anti-notch2 antibodies and conjugates and methods of use |
WO2023147399A1 (en) | 2022-01-27 | 2023-08-03 | The Rockefeller University | Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof |
TW202342519A (zh) | 2022-02-16 | 2023-11-01 | 瑞士商Ac 免疫有限公司 | 人源化抗tdp-43結合分子及其用途 |
US20230414750A1 (en) | 2022-03-23 | 2023-12-28 | Hoffmann-La Roche Inc. | Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy |
WO2023186756A1 (en) | 2022-03-28 | 2023-10-05 | F. Hoffmann-La Roche Ag | Interferon gamma variants and antigen binding molecules comprising these |
WO2023186760A1 (en) | 2022-03-28 | 2023-10-05 | F. Hoffmann-La Roche Ag | Improved folr1 protease-activatable t cell bispecific antibodies |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023194565A1 (en) | 2022-04-08 | 2023-10-12 | Ac Immune Sa | Anti-tdp-43 binding molecules |
WO2023201256A1 (en) | 2022-04-12 | 2023-10-19 | Vir Biotechnology, Inc. | High dose antibody therapies for sars-cov-2 infection |
WO2023201291A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of mosunetuzumab and methods of use |
TW202404637A (zh) | 2022-04-13 | 2024-02-01 | 瑞士商赫孚孟拉羅股份公司 | 抗cd20/抗cd3雙特異性抗體之醫藥組成物及使用方法 |
WO2023201299A1 (en) | 2022-04-13 | 2023-10-19 | Genentech, Inc. | Pharmaceutical compositions of therapeutic proteins and methods of use |
WO2023203177A1 (en) | 2022-04-20 | 2023-10-26 | Kantonsspital St. Gallen | Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof |
TW202406934A (zh) | 2022-05-03 | 2024-02-16 | 美商建南德克公司 | 抗Ly6E抗體、免疫結合物及其用途 |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023230445A2 (en) | 2022-05-23 | 2023-11-30 | Humabs Biomed Sa | Broadly neutralizing antibodies against influenza neuraminidase |
WO2023230439A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Fc-engineered hepatitis b virus neutralizing antibodies and uses thereof |
WO2023230448A1 (en) | 2022-05-23 | 2023-11-30 | Vir Biotechnology, Inc. | Combination immunotherapy for influenza |
WO2023240058A2 (en) | 2022-06-07 | 2023-12-14 | Genentech, Inc. | Prognostic and therapeutic methods for cancer |
WO2023237706A2 (en) | 2022-06-08 | 2023-12-14 | Institute For Research In Biomedicine (Irb) | Cross-specific antibodies, uses and methods for discovery thereof |
WO2023245078A1 (en) | 2022-06-15 | 2023-12-21 | Humabs Biomed Sa | Anti-parvovirus antibodies and uses thereof |
WO2024006472A1 (en) | 2022-06-30 | 2024-01-04 | Vir Biotechnology, Inc. | Antibodies that bind to multiple sarbecoviruses |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020564A1 (en) | 2022-07-22 | 2024-01-25 | Genentech, Inc. | Anti-steap1 antigen-binding molecules and uses thereof |
WO2024026411A1 (en) | 2022-07-27 | 2024-02-01 | Humabs Biomed Sa | Broadly neutralizing antibodies against rsv and mpv paramyxoviruses |
WO2024026447A1 (en) | 2022-07-29 | 2024-02-01 | Alector Llc | Anti-gpnmb antibodies and methods of use thereof |
US20240092859A1 (en) | 2022-08-18 | 2024-03-21 | Immunocore Ltd | T cell receptors and fusion proteins thereof |
WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024038198A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
WO2024052922A1 (en) | 2022-09-11 | 2024-03-14 | Yeda Research And Development Co. Ltd. | Anti-klk4 antibodies and uses thereof |
WO2024068572A1 (en) | 2022-09-28 | 2024-04-04 | F. Hoffmann-La Roche Ag | Improved protease-activatable t cell bispecific antibodies |
WO2024068705A1 (en) | 2022-09-29 | 2024-04-04 | F. Hoffmann-La Roche Ag | Protease-activated polypeptides |
WO2024068996A1 (en) | 2022-09-30 | 2024-04-04 | Centre Hospitalier Universitaire Vaudois (C.H.U.V.) | Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection |
WO2024077239A1 (en) | 2022-10-07 | 2024-04-11 | Genentech, Inc. | Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies |
WO2024079074A1 (en) | 2022-10-10 | 2024-04-18 | Universite D'aix Marseille | ANTI-sCD146 ANTIBODIES AND USES THEREOF |
WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
WO2024102734A1 (en) | 2022-11-08 | 2024-05-16 | Genentech, Inc. | Compositions and methods of treating childhood onset idiopathic nephrotic syndrome |
WO2024100200A1 (en) | 2022-11-09 | 2024-05-16 | Cis Pharma Ag | Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications |
WO2024100170A1 (en) | 2022-11-11 | 2024-05-16 | F. Hoffmann-La Roche Ag | Antibodies binding to hla-a*02/foxp3 |
WO2024104933A1 (en) | 2022-11-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Antigen binding molecules |
WO2024104988A1 (en) | 2022-11-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Recombinant binding proteins with activatable effector domain |
WO2024107749A1 (en) | 2022-11-16 | 2024-05-23 | Attralus, Inc. | Fusion proteins that bind amyloid and the transferrin receptor and uses thereof |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4997930A (en) * | 1989-03-16 | 1991-03-05 | Ciba-Geigy Corporation | Cloning of complementary DNA encoding maize nitrite reductase |
GB2325232B (en) * | 1996-02-14 | 2000-11-29 | Univ Alberta | Plants having enhanced nitrogen assimilation/metabolism |
-
2000
- 2000-10-02 AT AT00965684T patent/ATE303445T1/de active
- 2000-10-02 EP EP00965684A patent/EP1222292B1/en not_active Expired - Lifetime
- 2000-10-02 PT PT00965684T patent/PT1222292E/pt unknown
- 2000-10-02 CA CA002385347A patent/CA2385347C/en not_active Expired - Fee Related
- 2000-10-02 BR BR0014480-0A patent/BR0014480A/pt not_active Application Discontinuation
- 2000-10-02 DE DE60022369T patent/DE60022369T2/de not_active Expired - Lifetime
- 2000-10-02 CN CNB008138680A patent/CN100427603C/zh not_active Expired - Fee Related
- 2000-10-02 KR KR1020027004322A patent/KR100797667B1/ko not_active IP Right Cessation
- 2000-10-02 JP JP2001528606A patent/JP2003512821A/ja active Pending
- 2000-10-02 NZ NZ517906A patent/NZ517906A/xx not_active IP Right Cessation
- 2000-10-02 ES ES00965684T patent/ES2248127T3/es not_active Expired - Lifetime
- 2000-10-02 WO PCT/CA2000/001143 patent/WO2001025454A2/en active IP Right Grant
- 2000-10-02 MX MXPA02003456A patent/MXPA02003456A/es active IP Right Grant
- 2000-10-02 AU AU76358/00A patent/AU782626B2/en not_active Ceased
- 2000-10-03 US US09/678,300 patent/US6420548B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2385347A1 (en) | 2001-04-12 |
AU7635800A (en) | 2001-05-10 |
DE60022369D1 (de) | 2005-10-06 |
US6420548B1 (en) | 2002-07-16 |
KR20020057967A (ko) | 2002-07-12 |
PT1222292E (pt) | 2005-11-30 |
WO2001025454A2 (en) | 2001-04-12 |
CN100427603C (zh) | 2008-10-22 |
JP2003512821A (ja) | 2003-04-08 |
KR100797667B1 (ko) | 2008-01-23 |
ATE303445T1 (de) | 2005-09-15 |
ES2248127T3 (es) | 2006-03-16 |
AU782626B2 (en) | 2005-08-18 |
MXPA02003456A (es) | 2002-10-23 |
EP1222292A2 (en) | 2002-07-17 |
WO2001025454A3 (en) | 2001-11-08 |
BR0014480A (pt) | 2002-06-11 |
EP1222292B1 (en) | 2005-08-31 |
NZ517906A (en) | 2003-01-31 |
DE60022369T2 (de) | 2006-05-18 |
CA2385347C (en) | 2009-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1377419A (zh) | 调控外源基因转录的方法 | |
CN1154740C (zh) | 根皮层特异性基因启动子 | |
CN1171993C (zh) | 编码对n-乙酰基-l-膦丝菌素具有特异性的氨基酸脱乙酰酶的新基因,其分离和应用 | |
CN100347291C (zh) | 用于发酵制备l-半胱氨酸、l-胱氨酸、n-乙酰丝氨酸或四氢噻唑衍生物的微生物和方法 | |
CN1219064C (zh) | 植物脂肪酸去饱和酶启动子 | |
CN1024021C (zh) | 含谷胱甘肽s-转移酶基因的除莠剂耐性植物 | |
CN1063488C (zh) | Dna扩增 | |
CN1908174A (zh) | 生产l-赖氨酸的方法 | |
CN1993464A (zh) | 新羰基还原酶、其基因及它们的使用方法 | |
CN1161474C (zh) | 基因表达特异性的提高 | |
CN1609208A (zh) | L-丝氨酸的抑制性被降低的3-磷酸甘油酸脱氢酶变体及其编码基因 | |
CN1594571A (zh) | 百草枯抗性基因及维管束和毛状体特异性启动子 | |
CN1923850A (zh) | 水稻叶形控制基因sll1及其应用 | |
CN1582335A (zh) | 水稻转座子基因 | |
CN1185349C (zh) | 用于产生耐温植物的方法 | |
CN1195862C (zh) | 分离和纯化的包括在蛇麻腺中特异性表达的基因的核酸 | |
CN1086737C (zh) | 超热稳定蛋白酶基因 | |
CN1502701A (zh) | 生产D-N-氨基甲酰基-α-氨基酸的方法 | |
CN1230544C (zh) | 磷酸己酮糖异构酶和编码该酶的基因 | |
CN100339479C (zh) | 参与油菜素类固醇合成的基因 | |
CN1882692A (zh) | 包含非抗生素抗性选择标志物的选择系统 | |
CN1279714A (zh) | 环氧化物水解酶 | |
CN1756835A (zh) | 用作选择标记的转位酶 | |
CN1257269C (zh) | 一种生产7-氨基头孢烷酸的方法及其专用重组酶 | |
CN1295334C (zh) | 小麦抗病相关基因TaEDR1及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20081022 Termination date: 20111002 |